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ABSTRACT 
 Basal cell carcinoma (BCC) is the most common form of skin cancer.  It is caused by de-
regulated Hedgehog (HH) signaling, most often due to loss-of-function mutations in the HH 
receptor Patched1 (PTCH1).  Ptch1 deletion in mice yields BCC-like tumors that mimic human 
disease.  Using this model, I identified several epidermal populations that are susceptible to 
Ptch1-driven BCC formation.  These populations include the hair follicle (HF) isthmus and bulge 
regions, as well as the mechanosensory touch dome (TD).  In contrast, the interfollicular 
epidermis (IFE) is resistant to BCC initiation.  One striking difference in the micro-environment 
of the HF/TD versus the IFE is the presence or absence of innervation.  The HF/TD niches 
contain sensory nerves which secrete HH ligand to activate signaling, while the IFE lacks 
innervation.  Based on this observation, I chose to investigate the contribution of nerves to BCC 
tumorigenesis.  First, I found that surgical denervation reduces TD-derived tumor growth, which 
highlights a promoting role for nerves in BCC.  In addition, my preliminary data suggest hyper-
innervation via expression of nerve growth factor Neurotrophin-3 (NT-3) may enhance BCC 
initiation in the HF and TD compartments.  Despite the apparent promoting role for nerves in 
HF/TD BCC, ectopic innervation of the IFE via NT-3 expression is not sufficient to impart BCC 
susceptibility.  This suggests that additional mutations are required to overcome the IFE’s 
resistance to BCC formation.  Several in vitro and in vivo studies suggest that in the absence of 
Ptch1, HH signaling is mediated by its homologue Patched 2 (Ptch2).  However, I found that 
additional loss of Ptch2 does not affect BCC tumorigenesis or the level of HH activation.   
	 xv	
Together, this data highlight a novel role for sensory innervation in promoting BCC 
tumorigenesis, and uncovers a new potential therapeutic target for BCC treatment.   
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 It has been 20 years since researchers discovered Hedgehog signaling as the driver for 
basal cell carcinoma (BCC).  Since then, incredible advancements have increased our 
understanding of HH and BCC.   These advances have led scientists to develop effective targeted 
therapies, including the FDA approved HH inhibitors vismodegib and sonidegib, which are 
prescribed in the clinic today.  Despite these advances, HH inhibition likely has several on-target 
side effects, and tumors can become resistant.  Thus, further characterization of BCC is 
necessary to develop new, more effective treatments.  This chapter introduces the HH signaling 
pathway and its role in epidermal development, homeostasis and BCC.  I summarize key 
milestones in BCC research, and discuss tools used to model and study BCC.  I introduce the 
signaling events that mediate epidermal innervation and summarize the role of nerves in several 
cancer types and diseases.   Finally, I pose the key questions I will be addressing in following 
chapters.   
 
1.2 Hedgehog Signaling in the Epidermis 
 
1.2.1 Hedgehog pathway overview 
 Discovered almost 40 years ago, Hedgehog (HH) was first identified in a mutational 
screen for genes affecting Drosophila segment polarity [1, 2].   In vertebrates, HH signaling 
initiates when ligands (Sonic, Desert, or Indian HH [3-5]) bind the receptor Patched1 (PTCH1) 
[6, 7].  This binding relieves PTCH1’s inhibition of the downstream effector Smoothened (SMO) 
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[8-10].  Active SMO then facilitates GLI protein activation of target gene transcription, including 
the HH pathway members Ptch1 and Gli1 [11, 12].  In the absence of ligand, PTCH1 inhibits 
SMO and GLIs repress target gene transcription (FIG 1.1, reviewed in [13, 14]).    
In mammals, HH signaling requires the primary cilium, a cell surface “antenna” that 
senses external signals [15, 16].  In the absence of HH ligand, PTCH1 localizes to the primary 
cilium preventing SMO from entering [17].  Upon HH ligand binding, PTCH1 exits the cilium 
allowing accumulation of SMO and GLI [17-19].  Mutations in ciliary components disrupts HH 
signaling [16, 20].   
While Drospohila have one HH ligand [1],  mammals have three different HH ligands, 
Sonic, Desert, and Indian HH [3-5].  Sonic Hedgehog (SHH) is the primary activator of HH in 
the epidermis [21, 22].  SHH is a secreted ligand that undergoes several processing steps before 
it is functional in HH signaling.  Initially, SHH contains a signal sequence , signaling domain, 
and auto-processing domain.  First, the signal sequence is cleaved.  Next the auto-processing 
domain catalyzes a cholesterol transfer at the C terminus, allowing the peptide to associate with 
the membrane [23, 24].  Finally, SHH undergoes an N-terminal addition of a palmitoyl moiety, 
which is required for long range signaling [25-29].  SHH secretion is mediated by membrane 
bound Dispatched (DISP)[30-33] and secreted Scube (SCUBE) [34-36]. 
In addition to PTCH1, mammalian HH signaling is also regulated at the cell surface by 
co-receptors.   Positive regulators include GAS1, CDON, and BOC [37].  These co-receptors 
bind HH ligand and form complexes with PTCH1 to promote signaling [38].   GAS1, CDON, 
and BOC have distinct but overlapping roles in neural and limb patterning [37].  However, 
deletion of all three co-receptors causes almost complete HH blockade and early embryonic 
lethality, reminiscent of other HH loss-of-function mutants [37].   
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HH is negatively regulated at the cell surface by PTCH1, its homolog Patched 2 (PTCH2, 
[39]), and Hedgehog interacting protein (HHIP, [40]) which exists in both a membrane bound 
and secreted form.  All three of these receptors are also HH target genes.  Upon pathway 
activation, PTCH1/2 and HHIP are up-regulated in a negative feedback loop to suppress 
signaling.  As such, loss of PTCH1 [41], PTCH2 [42], or HHIP [43] causes varying degrees of 
HH activation.  As the primary HH receptor, Ptch1 deletion has the most severe developmental 
phenotype [41].  Ptch2 mutant mice are viable, but display a mild epidermal phenotype [42].  
Dual loss of the PTCH receptors results in higher HH activation than PTCH1 loss alone in vitro 
[44] and in vivo [45-47].  These studies indicate partial redundancy between PTCH1 and PTCH2 
inhibition of SMO in the absence of ligand.  Hhip mutant mice die postnatally, due to respiratory 
failure, however patterning of limbs, skin, and central nervous system is unaffected [43].   
Combined loss of PTCH1, PTCH2, and HHIP in the neural tube causes more severe defects than 
single mutants, highlighting the overlapping roles for these receptors in suppressing HH [45, 48].   
GLI proteins are the transcriptional effectors of the HH pathway.  Vertebrates have three 
GLI family members (GLI1-3).  GLI1 was first identified in glioblastoma [49].  GLI2/3 were 
later identified due to sequence similarity [50].  GLI proteins contain zinc-finger domains that 
allow them to bind DNA [51].  All three GLIs contain a C-terminal activation domain 
[52].   GLI2/3 (but not GLI1) also contain an N-terminal repressor domain [53, 54].   These 
domains allow modulation of target gene expression under different signaling conditions.   
Mouse studies have highlighted distinct roles for GLI1-3.  During development, GLI1 is 
expressed near sources of HH ligand, while GLI2/3 are expressed more broadly [55-57].  Gli1 is 
a HH target gene [58], and ectopic GLI1 mimics ectopic SHH activation in the neural tube [58, 
59].  Despite this promoting role, Gli1 mutant mice develop normally [60, 61].  Unlike GLI1, 
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GLI2 is required for proper development [62, 63].  In the neural tube, a ventral-dorsal HH 
gradient specifies different neural progenitors (reviewed in [14]).  Mutation of Gli2 causes a loss 
of ventral floor plate cells, which require the highest level of HH [62, 63].  However, Gli2 
mutants retain motor neurons, which require lower HH activation [62, 63].  This suggests that the 
neural tube requires GLI2 to activate high-level HH signaling.   Unlike GLI2, GLI3 inhibits HH 
activation, as loss of GLI3 causes ectopic HH activation [64-66].  Gli3 mutations in humans also 
cause Greig cephalopolysyndactyly syndrome, a disorder that affects the limbs, head, and face 
[67].  These studies suggest GLI3 functions primarily as a repressor, although full-length GLI3 
can activate transcription in vitro [53, 54, 68], and weakly in vivo [69, 70].    
 Combined mutational studies highlight overlapping and diverging roles for GLI proteins.  
In the neural tube and lung, dual loss of GLI1 and GLI2 causes a slightly more severe phenotype 
than loss of GLI2 alone [60].  This highlights a role for GLI1 (in certain tissues) in the absence 
of GLI2.  Limbs in Gli1/2 double mutants develop normally [63, 71], while Gli3 mutants display 
polydactyly [64-66], indicating a primary role for GLI3.  In addition, Gli2/3 double mutants 
display more severe skeletal defects than single mutants [72].  Taken together, these studies 
highlight functional redundancies in the GLI family.  
GLI processing is complex and not fully understood.  In the absence of HH, the 
activation domains of GLI2/3 are cleaved [54, 73].  This process is mediated by Protein kinase A 
(PKA)[54, 74, 75] , Casein Kinase 1 (CK1)[76], and Glycogen Synthase Kinases (GSKs)[76-78]. 
These phosphorylation events lead to ubiquitination and proteasome processing and/or 
degradation [79].  The repressor form of GLI2 is unstable [12, 75], which could explain why 
GLI3 has a more dominant repressor function in vivo [64-66].  GLI1 lacks the repressor domain 
and is not processed [53, 54, 80].    
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GLI processing is also regulated by Suppressor of Fused (SUFU) [81].  SUFU is a 
negative regulator of HH signaling [81].  As such, Sufu mutant mice display overactive HH 
signaling [82].  SUFU binding to full-length GLI2/3 prevents nuclear localization and promotes 
processing [83, 84].  PKA inhibits dissociation of this GLI-SUFU complex [84].      
Despite their conflicting transcriptional roles, GLI activators and repressors bind similar 
genomic sequences [85, 86].  Promoter studies suggest that multiple high- and low-affinity GLI 
binding sites can regulate expression of one gene [87, 88].  These sites tune the pattern of 
expression in specific tissues and cell types.  It is a complex system, where GLI activators and 
repressors bind and regulate each element based on context.  Careful examination of many target 
gene promoters will be necessary to unravel how this process is regulated.   
 
1.2.2 Epidermal development and hair follicle morphogenesis 
The epidermis derives from the surface ectoderm.  At embryonic day 12 (E12), the 
epidermis exists as a single layer of cells undergoing symmetrical divisions.  During the next few 
days (E13-15), basal cells, the lowest layer of the epidermis, undergo asymmetric cell divisions 
[89].  This creates a second suprabasal layer of the skin, directly above the basal layer [89].   
This layer continues dividing for a short period before undergoing a terminal differentiation 
program mediated by Notch signaling [90] (reviewed in [91]).  These suprabasal cells create the 
spinous layer of the skin, which contains bundles of Keratins 1 and 10 [92].  A few days later 
(E18.5), the epidermis further stratifies creating the granular layer, characterized by the presence 
of dense cytoplasmic keratohyalin granules, which promote dehydration and keratin crosslinking.   
The outermost layer, the stratum corneum, consists of cornified cells that confer barrier function 
(reviewed in [93]).    
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During stratification, dermal-epidermal cross-talk initiates hair follicle morphogenesis.  
Dermal condensates form along the basement membrane and signal via Fibroblast growth factors 
(FGFs)[94, 95] and Noggin [96] (E15).  Wnt signaling from the epidermis signals the formation 
of the hair germ or placode [97, 98] (E16).  These placodes express SHH, which induces 
condensation of dermal cells to form the dermal papilla (DP)[22].  The DP then signals the 
follicle to grow downward and envelop the DP (E18).  As the follicle matures, the cells at the 
base proliferate, generating the layers of the mature follicle and hair shaft (reviewed in [93, 99]) 
(FIG 1.2).   
 
1.2.3 The hair cycle 
Mature hair follicles cycle through phases of rest (telogen), growth (anagen), and 
regression (catagen).  Early anagen begins with proliferation in the secondary hair germ induced 
by Wnt, FGF, and BMP-inhibition signals from the DP [100].  During mid-anagen, the new 
follicle grows and envelops the DP.  Matrix cells are specified adjacent to the DP, and divide to 
form the inner layers of the follicle and hair shaft.  Once the new follicle forms, the lumens of 
the new and old follicles fuse through an unknown mechanism [101].  The shaft from the old 
follicle is lost through the process of exogen, or shedding, although the exact mechanism is 
unknown [102].  During catagen, proliferation ceases and the lower anagen follicle undergoes 
cell death and regresses.  The follicle then remains in telogen awaiting cycle activation (FIG 1.2, 





1.2.4 HH during epidermal development and homeostasis 
Hair follicles (HFs) require HH at several stages throughout epidermal 
development/homeostasis.  HF morphogenesis begins with placode formation.  This process 
requires Wnt signaling.  Animals lacking the Wnt effector b-catenin [106], or expressing the Wnt 
inhibitor DKK1 [107] do not form hair placodes, and fail to develop hair follicles.  Although HH 
is not required during HF initiation, established hair placodes express SHH ligand (SHH)[22, 
108].  As such, in Shh-/- animals, follicles halt after initiation [21, 108].  HH-blocking antibody 
(moAB) treatment on pregnant dams also causes stalling after HF initiation in newborn pups 
[109].   Abortive follicles in Shh-/- skin lack a recognizable dermal papilla (DP), and dermal 
condensates are negative for Ptch1 and Gli1 [21, 108].  Without SHH the DP fails to up-regulate 
several genes including Noggin, which is required for follicle maturation [110].   
In adult telogen skin, HH is active in three distinct cell populations. These include the 
secondary hair germ (SHG), the upper bulge region (UB), and the mechanosensory touch dome 
(TD) (FIG 1.3) [111].  Although embryonic skin expresses SHH, its expression in telogen 
epidermis is negligible. This indicates that HH ligand must be coming from a non-epidermal cell 
population.  Work from Brownell et al., showed that the UB and TD receive HH from the 
sensory nerves which innervate them [111, 112].  Removal of these nerves causes loss of HH 
activity in both the UB and TD compartments, but not the SHG.  This suggests that the SHG 
does not receive neural SHH [111, 112].  Although surgical denervation ablates HH activity in 
the UB, this does not affect the hair cycle [111, 113].   
HH is also important for hair cycling.  Hair cycle initiation is a two-step process that 
begins with activation of stem cells in the SHG [100].   The SHG receives signals from the 
adjacent DP.  These signals include BMP-inhibition [100], TGF-b [114], PDGF [115], and FGF7 
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[100].  The proliferating SHG gives rise to the hair follicle matrix, a population of transit 
amplifying cells which contributes to the growing anagen follicle [100].  A sub-set of matrix 
cells express high levels of SHH.  When SHH is absent, proliferation within the SHG is 
decreased and anagen cannot progress past initiation [100].  Reminiscent of HF development, 
SHH is required for anagen progression, but not initiation.  As such, HH monoclonal antibody-
treated telogen skin cannot progress through anagen [109].   In addition, human patients on 
vismodegib, a HH-antagonist, often develop alopecia (hair loss) [116].   
 1-2 days after the SHG begins to proliferate, the stem cells within the HF bulge become 
proliferatively active and migrate downward contributing to the growing follicle [117].  This 
activation requires SHH signaling from the SHG-derived matrix [118].  Matrix cells secrete SHH 
ligand, which in turn activates HH target genes within the HF bulge [118].  In the absence of 
SHH, bulge stem cells remain quiescent and fail to contribute to the growing follicle  [118]. The 
ability of bulge stem cells to respond to matrix-derived SHH is aided by the expression of HH 
co-receptor GAS1 [118].  GAS1 promotes HH activation within the bulge, and as such Gas1-/- 
animals display decreased proliferation in bulge stem cells [118].   
SHH from the matrix is also important for signaling between the HF and the DP.  In the 
absence of SHH, the DP fails to upregulate the BMP-inhibitor Noggin and FGF7, which are 
important for hair bulb proliferation [118].   
 
 
1.3 Innervation During Epidermal Development and Homeostasis 
 
1.3.1 Nerve functions in the skin  
Being able to sense the environment is essential for survival.  The epidermis contains 
several different types of nerve endings, with a diverse set of functions.  Epidermal nerves sense 
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temperature, acid, pain, touch, and pressure.  They then relay these signals to the brain triggering 
a response.   Epidermal innervation relies on neurotrophic factors.  The skin expresses these 
factors during development to maintain innervation (reviewed in [119]).   
In mammalian hairy skin, there are several different types of nerve endings.  Most 
cutaneous nerves have sensory functions, while a small subset has sympathetic function.  These 
sympathetic nerves are located exclusively in the dermis, where fibers innervate blood and 
lymphatic vessels, sweat glands, hair follicles, and the arrector pilli muscle (reviewed in [120, 
121]).   Cutaneous nerves vary in their myelination and adaptation speed to stimuli.  This 
variation allows their diverse functions.   There are two groups of nociceptive or pain-sensing 
nerves in the skin [122].  Myelinated Ad fibers are responsible for the “fast” and localized first 
response, while unmyelinated C fibers mediate the “slow” diffuse pain response [123].  Touch 
sensation is mediated by low-threshold mechanoreceptors, which contain myelinated Ab fibers 
(reviewed in [124]).  These Ab fibers are either slowly adapting (SA), which display sustained 
firing in response to stimuli, or rapidly adapting (RA), which fire at the start and end of 
stimulation [125].   SA and RA Ab fibers can be divided further into type I and type II fibers.   
SAI and SAII can be differentiated by their firing rates, receptive fields, and tuning properties 
[126].  RAI and RAII also differ in their receptive fields [127-129].   
This diverse group of sensory fibers are organized into nerve “end organs”.  These end 
organs are encapsulated nerve endings which sense specific stimuli such as sensation of skin 
stretch, pressure, vibration, and hair movement (reviewed in [130]).  Lanceolate endings wrap 
hair follicles.  They contain RA fibers to sense hair movement [131].  Free nerve endings are 
present throughout the epidermis.  They contain Ad and C-fibers to sense pain [132].  Touch 
domes (TDs) contain Merkel cell (MC)-neurite complexes.  They contain SAI fibers that sense 
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detailed spatial features [133].  Ruffini endings are present in the dermis, and contain SAII fibers 
thought to sense skin stretch [134].  Pacinian corpuscles, also located in the dermis, contain RAII 
fibers which sense vibration [135].  Meissner corpuscles are located in glabrous (non-hairy) skin 
and contain RAI fibers to sense object slip and grip [136].   
 
1.3.2 Innervation is linked to follicular development and homeostasis 
During development, sensory innervation coincides with hair follicle (HF) 
morphogenesis.  There are no nerves present in the epidermis prior to HF induction.  During 
early induction, nerve fibers branch towards stage 1 and 2 follicles (E16) [137].  At embryonic 
day 18, nerve fibers approach two target positions.  The first target is the HF opening, described 
as follicular (neural) network A (FNA).  The second is the region below the sebaceous gland, 
follicular (neural) network B (FNB) [138].  After birth, nerves secrete sensory neuropeptides 
Substance P (SP) and Calcitonin gene related peptide (CGRP), which facilitate neurotransmitter 
release [139, 140].  During anagen, branching continues and innervation around HFs, 
vasculature, and the arrector pili muscle increases in density and organization.  Nerve fibers in 
the FNB, which first appear circumferentially, branch longitudinally.  At P17, follicles begin the 
initiation of the first hair cycle.  Throughout cycling, FNA innervation decreases, while FNB 
innervation remains stable (FIG 1.4) [137].    
After morphogenesis, follicles continue to cycle through growth, regression, and rest 
phases.  As this cycling occurs, the follicle experiences many structural changes.  Not 
surprisingly, as these changes occur, the innervation pattern and density of the follicle and 
surrounding epidermis/dermis also changes (reviewed in [141]).   As the follicle enters anagen, 
innervation of both the FNA and FNB increases in density [138].  This is presumed to be via 
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increased expression of Neural Cell Adhesion Molecule (NCAM) and Growth Associated 
Protein 43 (GAP-43) which are involved in neurite outgrowth [138].   Innervation is also present 
around the newly formed anagen bulb, although in only a small percentage of follicles [138].  In 
addition to follicular innervation, the nerves throughout the dermis also experience remodeling 
throughout the hair cycle.  Dermal nerve fiber density and arborization of the deep cutaneous 
nervous plexus also increase in early anagen [138].  In late anagen, as follicles reach their peak 
growth, NCAM is down-regulated and innervation reverts to telogen levels [138].   
The link between innervation and hair follicle morphogenesis/cycling suggests a possible 
functional role for innervation.   Surgical denervation is a method that allows us to investigate 
how innervation affects skin function.  This technique involves making a dorsal-lateral incision 
and snipping or plucking the cutaneous nerves from where they exit the body wall and enter the 
skin (see chapter II for a more detailed description).  Nerves are removed or cut on one side of 
the mouse, leaving the other side as a sham operated control.  This allows comparison of 
denervated and intact skin from the same animal.   
Maurer et al., used this technique to examine whether intact innervation is important for 
hair follicle cycling [113].  In this study, both spontaneous and induced (via depilation or 
cyclosporine treatment) anagen were compared in intact and denervated skin.  Surprisingly, 
despite the temporal link between hair cycling and innervation changes, the group found no 
significant differences in anagen induction or progression.  These results indicate that 
innervation is not essential for hair cycling.   
Because innervation and HF morphogenesis begin in utero, surgical denervation is not a 
viable method to study the functional relationship.  However, mice which lack certain nerve 
growth factors, neurotrophins (see section 1.3.3), display defects in epidermal innervation and 
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can be used to overcome this challenge.  Mice which lack nerve growth factor (NGF) display 
initial epidermal innervation which diminishes throughout development.  These mice also 
display a delay in hair follicle initiation and growth [142].  Similarly, mice which are 
heterozygous for Neurotrophin-3 (NT-3) also display a delay [143].  In contrast, animals which 
over-express NT-3 in the skin display accelerated HF morphogenesis [143].  Although this 
method does not directly test whether innervation is essential for HF morphogenesis, it does 
suggest a potential role for epidermal-neural signaling during HF development.   
 
1.3.3 Neurotrophins are required for nerve maintenance and specificity of target innervation 
Several growth factors are essential for epidermal innervation.  As nerves branch towards 
their targets, neurotrophic factors bind receptors on nerve terminals.  These complexes are then 
internalized, activating signaling pathways which promote cell survival.  Neurons which don’t 
receive signal, undergo programmed cell death (reviewed in [119]).  
The epidermis expresses several neurotrophic factors including: nerve growth factor 
(NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT-3, NT-4).   
These 4 factors display ~50% conservation in amino acid sequence [144].  Neurotrophins bind a 
family of receptor tyrosine kinases (RTKs) called Tropomyosin receptor kinases (Trks) [145].  
Each neurotrophin binds fairly specifically with a Trk family member, where NGF binds TrkA, 
BDNF and NT-4 bind TrkB, and NT-3 binds TrkC, although it can also bind TrkA and B [146, 
147].  All neurotrophins also bind p75, a tumor necrosis factor superfamily member, which aids 
in binding specificity and affinity with Trk receptors [148-151].  Once bound, neurotrophin-
receptor complexes are transported to the sensory neuron cell body.  Then, through a series of 
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signaling events, gene expression changes support neuron survival, proliferation, outgrowth, 
synapse formation, and migration (FIG 1.5) [147].   
 Different neurotrophic factors recruit nerve fiber subtypes to specific regions in the 
epidermis.  NGF expression specifically recruits TrkA positive fibers.  These neurons display 
enrichment for CGRP and SP.   These TrkA positive nerves are either lightly myelinated or 
unmyelinated, and primarily sense pain as free nerve endings [152].  NT-3-TrkC promotes 
survival of slowly adapting type I fibers (SAI), which innervate TDs.  In NT-3-/- animals, SAI 
fibers are absent and TDs are gradually lost, along with associated MCs [153].  Both Meissner 
endings (in glabrous skin) and hair follicle endings require BDNF/TrkB signaling [154].  NT-4 
overexpression causes enlarged Meissner endings, but NT-4 knockout animals have no 
significant defects in epidermal innervation [155], perhaps due to redundancy with BDNF.    
 
1.3.4 GFL family promotes cutaneous nerve survival 
 Like Neurotrophins, the Glial cell line-derived neurotrophic factor (GFL) family also 
promote nerve survival.  GFL family members include: GDNF, Artemin, Neurturin, and 
Persephin.  These GFL ligands signal through a receptor complex containing a specific GFL 
receptor (GFRa1-4), and Ret tyrosine kinase.  GDNF supports nociceptive (pain sensing) 
neurons in the skin [156], while Artemin overexpression leads to increased hot and cold 
sensitivity [157].  Neurturin overexpression in the skin also causes increased sensitivity to 
chemical, thermal, and mechanical stimuli [158], while Persephin doesn’t appear to have a role 




1.4 The Touch Dome: A Mechanosensory Organ 
1.4.1 Merkel and his cells 
In 1875, Friedrich Merkel observed a novel population of large clear oval cells associated 
with cutaneous nerves [160].  Based on their location, Merkel called these cells “tastzellen” or 
“touch cells”.  This population is now referred to as Merkel cells (MCs).  MCs are present in 
glabrous and hairy skin.  In glabrous skin, MCs are located near sweat gland ridges, and 
sporadically throughout the basal layer of the epidermis.  In murine hairy skin, MCs are present 
within a mechanosensory organ called the touch dome (TD) and in vibrissa follicles present in 
the whisker pad.  The TD, originally named haarscheibe or “hair disc”, was characterized by 
Felix Pinkus in 1902.  Pinkus described TDs as specialized discs of epithelial cells [161, 162].  
Later, William Straile discovered the association of mouse TDs with large tylotrich follicles, the 
largest and first to appear during development [163].  Ainsley Iggo confirmed TD innervation 
and mechanosensory ability in 1969 [133].  In mouse skin, TDs have two compartments, a 
columnar epidermal compartment comprised of Keratin 17 (K17) positive keratinocytes, and 
underlying neuroendocrine-like MCs expressing simple Keratins 8, 18 and 20 (K8, K18, K20) 
(FIG 1.6) [164-168].  These underlying MCs are associated with slowly adapting type 1 nerve 
fibers (SA1) [133].     
 
1.4.2 TD development requires a complex signaling cascade 
Mouse TDs are associated with tylotrich follicles, also called “guard” hairs.  As such, 
their development is linked.   Guard hair follicle induction begins at embryonic day 14 (E14) 
[169].  One day later (E15), MCs are present near guard hair germs.  MCs surround the guard 
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hair canal, or infundibulum until birth.   Then, they migrate into a characteristic crescent shape, 
located caudal to the follicle [170, 171].  
The TD requires many factors for development and maintenance.  These factors include 
ATOH1, SHH, and others.  MC specification requires the helix-loop-helix transcription factor, 
ATOH1 [172, 173].  Expression of ATOH1 is also sufficient to drive ectopic MC production in 
the epidermis [174].  MC specification also requires SHH, and SHH-/- skin does not form MCs 
[170].  SHH over-expression in the skin results in ectopic MC production [175].  Although all 
HFs express SHH, MCs are only present near guard follicles.  Polycomb repressor complex 2 
(PCR2) activity in non-guard follicles prevents MC formation.   As such, loss of the PCR2 
complex results in ectopic MC formation near non-guard follicles [175].  MC development relies 
on HF-derived SHH; however it’s important to note that most MCs are not derived from the 
SHH positive HF lineage [170]. 
The origin of MCs has been controversial.  Merkel cells express both epidermal (keratins) 
and neuroendocrine markers.  Early reports suggested a neuroendocrine lineage [176], but more 
recent reports suggest MCs derive from a Keratin 14 (K14) positive progenitor [177, 178].  Other 
studies suggest that in hairy skin, MCs come from the K17+/GLI1+ epidermal TD  [112, 179].  
The controversy over MC origin stems from the apparent slow turnover of these cells, which 
makes tracing difficult.  Lineage tracing experiments have suggested that MCs can have a 
lifespan of up to 7 weeks [112, 179, 180].   However, these results are contradicted by a recent 
study from Marshall et al., who observed rapid remodeling of MCs and TD innervation 
throughout the hair cycle [181].  During anagen, MCs and light touch response diminishes, but 
returns when follicles re-enter telogen.  Remodeling during the hair cycle has been previously 
reported, although these studies observed the opposite phenomenon, an increase in MCs during 
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anagen [182, 183].  This difference in observations could be due to species specificity, as many 
initial MC studies were performed in rats, or due to sampling methods.  Based on these 
conflicting results, more detailed studies are required for full understanding of Merkel’s cells.   
 
1.4.3 Innervation is required for TD maintenance 
Although TD keratinocytes are derived from the K14 positive ectoderm, resident stem 
cells maintain the adult TD.  These stem cells require innervation for maintenance.  Sensory 
nerves that innervate the TD secrete SHH ligand to activate HH signaling.  As such, surgical 
denervation or Shh deletion in nerves results in loss of TDs [112, 184].   
Together, these studies suggest that resident stem cells in the TD potentially maintain TD 
keratinocytes and underlying MCs.  However, more recent studies suggest uni-potent ATOH1+ 
progenitors maintain MCs [180].  Perhaps, within the TD there are two pools of progenitors:  
K17+/ATOH1- cells that maintain TD keratinocytes, and K17+/ATOH1+ cells that maintain the 
MC population [180].   
 
1.5 Basal Cell Carcinoma: A Hedgehog-Driven Cancer 
 
1.5.1 Introduction to BCC 
Basal cell carcinoma (BCC) is the most common human cancer, with millions of new 
cases in the United States each year [185, 186].  BCC was first described in the late 1820’s by 
Dr. Arthur Jacob [187], and was named after its histological resemblance to the basal cells of the 
epidermis [188].  BCC tumors most often occur on regions of sun-exposed skin, especially the 
face and scalp [189] (reviewed in [190, 191]), and BCC has several subtypes.  Superficial BCCs 
(sBCC) are flat lesions with fine telangiectasias, small erosions, and changes in pigmentation.  
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Nodular BCCs (nBCC) appear as raised lesions with large tumors nests.  Invasive BCCs (iBCC) 
appear as structure-less, flat, shiny red lesions [192].  All BCC tumors are caused by deregulated 
HH signaling, regardless of subtype (reviewed in [193, 194]).  
 
1.5.2 BCC and Hedgehog  
HH was discovered as the cause of BCC through sequencing patients with Gorlin 
syndrome, an autosomal dominant disorder also known as nevoid basal cell carcinoma syndrome 
(NBCCS) [195-198].  Gorlin patients develop many BCCs throughout their lifetime.  They also 
display other abnormalities including pitted palms and soles, and predisposition for several other 
tumor types including medulloblastoma (MB) [199].  Gorlin syndrome maps to chromosome 
9q22.  This region contains the gene encoding the HH pathway receptor PTCH1 [195, 197].  
Loss of function mutations in PTCH1 cause up to 90% of BCC tumors.  These mutations prevent 
PTCH1 from inhibiting SMO, rendering the pathway constitutively active.   Gorlin patients 
harbor germline mutations in one copy of PTCH1.  For these patients, BCCs occur when the 
remaining copy sustains a loss-of-function mutation.  Although PTCH1 mutations cause most 
BCCs, activating SMO mutations cause a subset (~10%) of BCC tumors (FIG 1.7) [200].   
 
1.5.3 Targeting Hedgehog in BCC 
The most common treatment for BCC is surgical excision.  Often this is curative.   Some 
BCCs which are invasive, or occur in areas that are difficult to resect, such as the eyelid, cannot 
be surgically removed.   Surgical resection is also not practical for Gorlin patients who can 
develop hundreds of BCCs.  These patients benefit from alternative treatments, such as 
pharmacological HH inhibition.   
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In the 1960s, farmers observed a strange phenomenon in their livestock.   Cows and 
sheep fed Veratrum californicum, a wild corn lily, gave birth to calves with holoprosencephaly 
(HPE).  HPE results in an absence of midline facial structures with a proboscis and a cyclopic 
eye [201-204].  In 1996, Chiang et al., linked this observation to HH when they observed a 
similar phenotype in mice lacking Sonic hedgehog (SHH) [205].  In addition, humans with SHH 
mutations also display a similar phenotype [206, 207].  The teratogenic effects of V. californicum 
come from the alkaloid cyclopamine [208-210].  Cyclopamine inhibits HH signaling via direct 
binding to SMO [211-214].  
Cyclopamine is not effective for treating BCC due to toxicity.   However, it did 
highlight SMO as a potential target to treat BCC [215].  Several compounds now exist that 
inhibit SMO.  One compound, vismodegib, is currently prescribed for Gorlin patients and 
advanced/metastatic BCC patients [216-218](reviewed in [219]).  In phase I clinical trials, 
approximately 50% of patients with advanced BCC responded to treatment.  Some patients even 
showed full regression of tumors [116].  In trials on Gorlin patients, vismodegib regressed most 
existing tumors, and prevented new lesion formation [220].  Despite the potency of vismodegib, 
often this treatment is only effective when patients remain on the drug.  Tumor nodules disappear 
upon drug treatment, but regrow when treatment stops [221-223].  This indicates that treatment is 
ineffective in completely ablating tumor initiating cells.  Additionally, there are significant side 
effects of constant HH blockade.  These include muscle cramps, alopecia, ageusia (loss of taste), 
and others.  These side effects can diminish quality of life for patients on vismodegib [220].  
Besides the side effects, tumors can also be or become resistant to vismodegib.  In phase I 
and phase II clinical trials on advanced and metastatic BCC, 30-50% of patients showed a 
response to treatment [116, 217, 218], suggesting that 50-70% of these patients displayed 
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resistant disease.  Resistant tumors either have primary mutations in SMO, or they 
acquire additional mutations during treatment.  These acquired mutations are most often in SMO, 
but in rare cases other downstream HH factors [221, 224-226].   Several SMO mutations within 
and outside the vismodegib binding pocket can confer drug resistance.  Mutations outside the 
binding pocket can also increase the baseline activity of SMO.  These mutations could be 
oncogenic drivers of BCC.  Mutations in HH factor Suppressor of Fused (SUFU) and 
amplification of GLI2 also can confer resistance to vismodegib, but are not usually primary 
drivers [225, 227].    
 In addition to vismodegib, there are several other inhibitors that bind SMO [228-232].  
Many of these inhibitors are structurally similar to vismodegib.  Sonidegib, is a structurally 
similar SMO inhibitor that recently gained FDA approval for treatment of BCC [233].  
Itraconazole is an FDA-approved antifungal that can inhibit SMO at a site distinct from 
vismodegib [234].  Although SMO inhibition can be effective to treat BCC, SMO mutations are 
a leading cause of drug resistance.  Exome sequencing of resistant BCCs uncovered SMO 
mutations in 42% of tumor samples [225].  Therefore, targeting the HH pathway downstream of 
SMO is an attractive alternative.  PSI, an atypical protein kinase C i/l (aPKC i/l) inhibitor, 
inhibits HH by blocking GLI activation.  It also can inhibit BCC growth [235].    Arsenic trioxide 
also inhibits HH activity, by promoting GLI degradation [234].   However, clinical trials 






1.6 Mouse Models of BCC 
 
1.6.1 Introduction 
 To study BCC, we use a variety of mouse models.  These models serve as tools to aid in 
the understanding of BCC, and to develop/test new treatments.  The following represents a brief 
introduction to the contributions these models have made to our understanding of BCC.   
 
1.6.2 Sonic hedgehog overexpression (embryonic) 
To model BCC in mice, Anthony Oro et al., generated a transgene containing Shh 
downstream of the Keratin 14 (K14) promoter (K14-Shh) [237].  This promoter is active at 
embryonic day 9.5 in the ectoderm, and later in the developing epidermis [238, 239].  K14-
Shh mice display skin and skeletal abnormalities resulting in perinatal lethality.  Importantly, 
these mice display increased expression of HH target genes (Ptch1) and BCC-like proliferations 
throughout the epidermis.  Skin transplants from K14-Shh mice 
onto scid/scid mice form microscopic BCC lesions [237].   These animals represent the first 
mouse model for human BCC, and highlight Shh as a potential oncogene in human cancers.  
However, a major limitation of this study is that Shh is not a primary driver of human BCC. 
 
1.6.3 Mutant Smoothened expression (embryonic) 
In addition to loss of Ptch1, mutations in Smo can also drive BCC [200].  One of the first 
mutations identified in patients contained a G1604T mutation.  The resulting protein variant was 
named SMO-M2 [200].  To test the oncogenic potential of SMO-M2 in-vivo, Xie et al., cloned 
the mutated sequence downstream of the Keratin 5 (K5) promoter (K5-Smo-M2) [200].  K5 
drives expression throughout the epidermis [240].  Unlike the K14-Shh mice, K5-Smo-M2 skin 
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macroscopically appears normal. These mice also lack the severe skeletal abnormalities seen in 
K14-Shh animals.  However, upon microscopic examination, K5-Smo-M2 skin displays 
characteristics reminiscent of human BCC.  These mice display widespread epidermal 
hyperplasia, with lesions branching into the dermis, and increased expression of Ptch1.  This is 
much like the phenotype seen in K14-Shh mice [200, 237].  Overall, this model identified 
activated SMO as a driver for human BCC.  Unlike the K14-Shh model, K5-Smo-M2 mice 
provided a direct model designed from patient mutations.   
To overcome the embryonic lethality of SMO-M2 expression, Grachtchouk et al., 
generated transgenic mice expressing SMO-M2 under the control of the DK5 promoter.  This 
truncated 1.3kb version of the K5 promoter drives expression in a subset of cells that express K5 
[241-243].  The epidermis of DK5-Smo-M2 is HH-active and hyperproliferative.  However, these 
lesions do not resemble BCC [244]. They instead more closely resemble basaloid follicular 
hamartomas (BFH), benign slow growing skin tumors that resemble primitive hair follicles 
[244].  When compared to lesions from K5-Smo-M2 mice and K5-Gli2 mice (see section 1.6.5), 
BFH lesions display decreased HH target gene expression and lack expression of G1 cyclins, D1 
and D2 [244, 245].    
 
1.6.4 Patched1 +/- plus radiation (UV/IR) 
 Ptch1 mutations cause BCCs in Gorlin patients, as well as in sporadic BCC 
patients.  Unfortunately, Ptch1-/- mice do not survive, making them unsuitable for adult BCC 
studies [41].  Ptch1+/- mice display many characteristics of Gorlin syndrome including 
polydactyly and predisposition for medulloblastoma.  However, they do not develop BCCs [41, 
246].   Mutagenic chemicals, ultraviolet (UV) or ionizing (IR) radiation also do not cause BCCs 
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in wild type mice [247].  However, when Ptch1+/- mice receive UV or IR, micro- and 
macroscopic BCCs and trichoblastomas form after 6-12 months [248, 249].  Sequencing of these 
lesions revealed loss of heterozygosity of Ptch1.  In addition, a subset of tumors had mutations in 
the tumor suppressor p53.  This is consistent with human BCC sequencing data [248, 250, 251].    
 
1.6.5 Overexpression of GLI transcription factors (embryonic) 
The GLI family of proteins (GLI1-3) act as transcriptional effectors of the HH signaling 
pathway [49-51].  Grachtchouk et al., tested the ability of GLI2 to drive BCC formation by 
cloning GLI2 downstream of the bovine K5 promoter [244].  This promoter drives expression in 
the basal layer of the skin and hair follicles [243].   These mice form macroscopic tumors by 3 
months of age, many of which resemble human BCC.  These BCC-like lesions display increased 
expression of HH target genes, and BCC markers including Keratin 17 (K17), Bcl-2, and K5 
[245].  These mice represent one of the first models for BCC in adult animals.  They also 
highlight GLI2 as an important effector of HH signaling in BCC.   
To test whether GLI1 is a downstream HH effector in BCC, Nilsson et al., cloned GLI1 
downstream of the bovine K5 promoter [252].  These mice develop tumors within 1-13wks of 
birth, and die prematurely between 1-6 months.  Tumors include nodular and superficial BCCs, 
trichoepitheliomas, and trichoblastomas.  Sequencing of these tumors revealed no mutations in 
known oncogenes P53 and RAS, indicating that GLI1 is sufficient to drive cutaneous tumor 





1.6.6 Mutant Smoothened expression (adult) 
          Activating mutations in SMO account for approximately 10% of human BCC tumors 
[200].  Embryonic expression of oncogenic SMO-M2 results in a BCC phenotype.  However, 
these mice are not viable and therefore an indirect model to study adult BCC [200].  Animals that 
express Smo-M2 under the DK5 promoter are viable, but do not develop BCC [244].  Because 
most BCCs arise in adult patients [116, 253], a conditional model of Smo-M2 expression 
provides a more direct model for human BCC.  Mao et al., developed an inducible system, where 
a conditional Smo-M2 allele is cloned downstream of the ubiquitous Rosa26 promoter (Rosa26-
Smo-M2) [254, 255]. When combined with different tamoxifen inducible Cre recombinase 
drivers, this allele allows for spatial and temporal control of SMO-M2 expression.  Combination 
of conditional Smo-M2 with a ubiquitous Cre-ER allele (CAAGS-Cre-ER) yields several tumor 
types including rhabdomyosarcomas, medulloblastoma, and BCCs [255].   
            To study the effect of SMO-M2 expression in adult skin, Youssef et al., combined the 
Rosa26-Smo-M2 allele with K14-CreER[256].  This drives SMO-M2 expression in the basal 
cells of the epidermis [257].  These mice develop microscopic BCCs 8 weeks after induction  
[256].   In contrast, SMO-M2 expression in hair matrix cells does not yield BCC tumors [256].  
Likewise, expression in bulge cells using various drivers does not induce BCC tumors [256].  
Low dose induction of K14-CreER; Rosa26-SMO-M2 mice results in tumors derived from the 
interfollicular epidermis.  These mice also had rare tumors derived from the infundibulum, or 
hair follicle opening [256].  Overall, this study suggests an interfollicular cell of origin for SMO-
M2-driven BCC.   
         Follicular stem cells are unable to form tumors upon SMO-M2 expression.  However, upon 
wounding these cells migrate to the wound site, where they acquire the ability to initiate BCC 
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tumors [258].  Taken together, these results suggest that the microenvironment can influence 
SMO-driven BCC formation.   
 
1.6.7 Conditional Patched1 deletion (adult) 
Conventional Ptch1 knockout mice are not viable, and the Ptch1 +/- plus radiation model 
is indirect, due to the unknown tumor genotype.  Therefore, conditional alleles of Ptch1 present a 
more experimentally tractable model for human BCC tumors.  Combining conditional alleles 
with Cre recombination drivers allows temporal and spatial control of Ptch1 deletion.  There are 
several conditional Ptch1 alleles used to study BCC tumorigenesis.   
Ptch1neo/neo mice allow conditional deletion of exon 3 of PTCH1.   Exon3 deletion via 
a ubiquitous Cre-driver is lethal at E9.5-10, consistent with conventional knockouts [259]. 
However, deletion using K6-Cre (coupled with Retinoic Acid (RA) treatment to increase 
recombination) causes BCC in 100% of animals after 16 weeks [260-262].   Exon 3 deletion 
using K14-Cre yields tumors by 3-4 weeks [263].  Similarly, Ptch1 deletion using MX1-Cre (a 
widespread driver) causes BCC at 8-10 weeks [263].   
Ptch1c/c mice allow conditional deletion of exon 2 [264], and PtcF1-2m mice allow 
conditional deletion of exons 1B, 1, 1A, and 2 [265].  Alternative splicing events make these 
models “leaky” in their ability to delete Ptch1, and less ideal for BCC studies [266].   
Ptch1neo(fl)Ex2(fl) mice allow conditional deletion of exon 2[267].  When combined with K5-
Cre*PR1[268], which upon RU486 administration drives recombination in epidermal basal cells, 
BCC tumors form throughout the skin [267].  Like the SMO-M2 model, wounding enhanced the 
formation of BCC-like lesions [258, 267].   
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Ptch1lox mice allow conditional deletion of exon 3 [259].  Combination of Ptch1lox alleles  
with K14-Cre, which drives recombination primarily in follicular basal cells of the epidermis 
[269], strikingly has little effect on epidermal development [46].  However, between 24-28 days 
post birth K14-Cre;Ptch1lox mice develop BCC-like lesions [270].  In contrast, deletion of Ptch1 
with K5-Cre, which drives broad recombination through the epidermis and follicles, is perinatal 
lethal [46].  These mice display disturbed hair follicle morphogenesis and mild epidermal 
hyperplasia, which does not resemble BCC.  When Ptch1lox alleles are deleted in adult epidermis 
using tamoxifen inducible K14-CreERT2 [271], mice display only a mild hyperplastic phenotype 
after 4 weeks [46].   
Ptchflox mice allow conditional deletion of exons 8 and 9 [272].  These mice do not 
display any “leaky” expression or disturbed splicing, and as such are ideal for tumor studies 
[272].  Exon 8+9 deletion via Rosa26-CreERT2 causes microscopic BCC-like tumors 45 days 
after induction with tamoxifen (TAM).  These tumors form preferentially in ear and tail skin 
[273, 274].   Deletion with K5-Cre-ERT [275], causes BCC-like tumors in ear, tail, and hairy skin 
post TAM [274].  However, BCC tumors also arose in control animals (K5-Cre-ERT;Ptchflox/flox, 
no tamoxifen administration).  This highlights leaky recombination activity of K5-Cre-ERT in 
this model [274].    
Since Ptch1 mutations drive most human BCC tumors, conditional Ptch1 alleles present 
the most representative model for BCC.  However, differences in tumorigenic response to these 
conditional alleles highlight the requirement for careful characterization of these models.  Based 
on the above results, in some contexts epidermal populations resist Ptch1-driven BCC formation 
[249, 267], while follicular deletion of Ptch1 reliably induces BCC-like tumors [46, 262, 263, 
267, 270, 273, 274].  To fully understand the cell of origin for Ptch1-driven BCC tumors, alleles 
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that display minimal “leaky” expression and disturbed splicing, such as the Ptch1lox and Ptch1flox 
alleles should be combined with reliable, tissue-specific inducible Cre recombinase drivers.  By 
carefully examining the response of epidermal compartments to Ptch1 deletion, we will better 
understand the human disease.   
 
1.6.8 Overexpression of GLI transcription factors (adult) 
Full-length GLI2 serves as a weak transcriptional activator, and is able to induce BCC 
formation after 4 months of expression [244].  However, removal of the N-terminal repressor 
domain allows GLI2 to act as a more potent activator of HH signaling [276, 277].   To 
investigate the tumorigenic response to GLI2DN expression, Grachtchouk et al., utilized a multi-
allele tetracycline-controlled expression system.  In this model, Gli2DN is cloned downstream of 
a tetracycline responsive element (tetO-Gli2DN) [278].  This element requires doxycycline 
(doxy) administration in the animal’s food or water, and tetracycline (rtTA), which in this system 
is expressed conditionally under the control of the ubiquitous Rosa26 promoter (Rosa26-LSL-
rtTA).  Conditional expression of rtTA requires deletion of a floxed stop cassette by Cre 
recombinase.  When combined with a tissue specific Cre driver, this system allows Gli2DN to be 
turned on (+doxy) and off (-doxy).  In this study, Grachtchouk et al., used K15-CrePR1 which 
drives recombination in the lower hair follicle upon RU481 administration [279].   In the 
presence of doxy, microscopic BCCs arise in K15-CrePR1;Rosa26-LSL-rtTA mice after 3 weeks 
[278].  These tumors are nodular and derive from the secondary hair germ or lower bulge.  
Gli2DN expression driven by Lgr5-CreER, which requires tamoxifen and is active in a more 
restricted population of the lower bulge and SHG, also causes nodular BCCs [278].  Broad 
targeting of the epidermis via K14-rtTA or K5-CreER;Rosa26-LSL-rtTA causes widespread 
	 27	
tumorigenesis.  These tumors derive from the interfollicular epidermis, sebaceous glands, and 
secondary hair germ.  This study highlights the variation in tumor initiating ability amongst the 
basal cells of the epidermis.  However, GLI2 mutations do not drive human BCC, and therefore 
this model does not directly mimic human BCC mutation status.  As such, this remains a 
powerful model for epidermal transformation, but perhaps not ideal for BCC cell of origin 
studies.   
 
1.6.9 Summary and future directions 
Over the last 20 years, mouse models have given us insight into the genetic basis, cell of 
origin, and tumor dynamics of BCC.  These models have highlighted several potential oncogenes 
capable of driving transformation in the skin and other organs.  These include SHH, GLI1/2, 
SMO, and the tumor suppressor PTCH1.  Variation in tumor initiating ability has uncovered 
different cells of origin for BCC.  Different cell populations rely on specific mutations and levels 
of oncogenic signal to form tumors.  For example, it appears that Smo-M2 expression via an 
unnatural promoter in adult mice promotes tumor formation primarily in the interfollicular 
epidermis (IFE) [256].  In contrast, Ptch1 deletion in adult mice drives follicular derived tumors 
[249, 267].  Expression of Gli2DN causes tumors derived from several epidermal compartments 
[278].  As research continues, careful dissection of how each epidermal population responds to 
HH activation is necessary.  Studies should employ models that directly mimic human disease, 
through inducible deletion of Ptch1 and expression of Smo-variants within specific sub-
compartments of the epidermis.  This will result in more effective targeted therapies and a better 
prognosis for BCC patients.   
 
	 28	
1.7 Neural Influence in Cancer 
1.7.1 Targeting nerves in cancer 
 In the past, cancer studies have focused on the acquired mutations which cause tumors 
and confer drug resistance.  However, more recent studies have begun to look at cancer from the 
perspective of the tumor microenvironment.  These studies have given new insight into tumor 
growth mechanisms, uncovering new therapeutic targets.    The tumor micro-environment 
consists of immune cells, blood vessels, nerves, fibroblasts, and the extra-cellular matrix (ECM).   
Numerous studies have investigated the roles for each of these cell populations in promoting 
tumor growth and metastasis (reviewed in [280, 281]).   
Peripheral nerves innervate all tumor-prone organs, such as the skin, stomach, pancreas, 
and prostate.  As such, the microenvironment of tumors within these tissues includes nerves.  
However, a promoting role for nerves in cancer has only gained traction in the last several years.   
One early indication of a role for nerves in promoting cancer was the correlation between peri-
neural invasion and poor prognosis (reviewed in [282]).  In addition, in vitro co-culture of cancer 
cells with nerve cells promotes proliferation, and in vivo neural stimulation can promote 
metastasis in several cancer types [283-287].   
 Direct evidence that neurogenesis promotes cancer progression and metastasis came from 
Magnon et al., in 2013 [288].  In this study, Magnon et al., used both chemical and surgical 
denervation to assess the role of nerves in prostate cancer.  Their results suggest two distinct 
roles for innervation in promoting prostate adenocarcinoma.  Adrenergic fibers support tumor 
initiation by promoting cell survival via b2 and b3-adrenergic receptors [288].  In contrast, 
cholinergic fibers promote metastasis through Cholinergic Receptor Muscarinic 1 (CHRM1) 
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signaling [288]. They also found an association between increased nerve density and poor 
prognosis in human samples [288].     
 Chemical and surgical denervation can slow disease progression in several animal models 
of cancer.  Sympathectomy improves survival of rats injected with BP6-TU2 fibrosarcoma cells, 
presumably by disrupting norepinephrine mediated proliferation of tumor cells [289].  Surgical 
and chemical denervation also suppresses tumorigenesis in mouse gastric cancer models 
potentially through disrupting Wnt signaling [290].  Chemical denervation using capsaicin also 
delays tumor formation in pancreatic ductal adenocarcinoma models by inhibiting inflammation 
associated with oncogenic Kras expression [291].   
 
1.7.2 A potential role for nerves in BCC 
 The epidermis displays dense and diverse innervation (see chapter 1.3).  Since nerves 
promote other epithelial cancer types, one can imagine a promoting role in BCC 
tumorigenesis.  In addition, cutaneous nerves promote psoriasis through Calcitonin gene related 
peptide (CGRP) signaling [292], and sympathetic innervation promotes growth of melanoma 
tumor cells through an unknown mechanism [293].    Epidermal sensory nerves also secrete HH 
ligand to activate signaling (see chapter 1.2) [111].  The ability of these nerve to 
activate HH make them an intriguing target for a HH-driven cancer like BCC.    
 
1.8 Summary and Remaining Questions 
 Recent progress has increased our understanding of BCC.  Yet, to further advance we 
must address new questions.  One area of controversy that remains is the cell of origin for 
BCC.  Heterologous mouse models have highlighted variation in the skin’s response to HH 
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deregulation.  This has clouded our interpretation.  Moving forward, it is important to narrow our 
focus to models which most closely mimic human BCC.  In addition, we must design 
experiments that allow us to study all aspects of disease progression. This includes tumor 
initiation, growth rate, response to treatment, resistance, and recurrence.    
 The role of the tumor microenvironment for BCC is an important aspect of BCC biology 
that has yet to be fully characterized.   Resistance presents a major barrier to effective targeted 
therapy.  As such, the microenvironment presents a potential alternative therapeutic target.    
I have focused my doctoral research on the following questions.  Mainly: “What is the cell of 
origin for BCC?” and “Can cutaneous nerves promote BCC tumorigenesis?”.  
 In chapter II, I discuss denervation as a tool for studying neural influence in normal and 
pathogenic skin.  In chapter III, I first address the question of BCC cell of origin.  For this study, 
I delete Ptch1 in distinct cell populations and assess tumor growth.  Also in chapter II, I begin to 
look at the role of nerves in BCC.  For this, I use surgical denervation and evaluate the effect on 
tumor growth.  In chapter IV, I characterize tumor formation in a hyper-innervated mouse 
model.  Finally, in chapter V, I discuss the role of PTCH1 homologue Patched 2 (PTCH2) in 











Figure 1.1: The Hedgehog (HH) signaling pathway. (Left) In the absence of signal, PTCH1 
inhibits SMO and GLIs are processed allowing them to repress target gene expression.  (Right) 
In the presence of signal, HH ligand binds the receptor PTCH1, relieving inhibition of 





























            
Figure 1.2: Hair follicle morphogenesis and cycling.  Hair follicle morphogenesis initiates 
with dermal cells forming condensates along the epidermis.  These condensates signal to the 
overlying epidermis to thicken and form the hair placode.  Cross-talk between the dermal 
condensate (dermal papilla, DP), and the hair placode facilitates downward growth into the 
dermis.  As the follicle grows it envelopes the DP, and cells at the base proliferate and 
differentiate to form the layers of the mature follicle and hair shaft.  After the initial growth 
phase (anagen), the lower follicle undergoes cell death and regression (catagen) before entering 
the rest phase (telogen).  The follicle remains in telogen until anagen is initiated spontaneously or 











Figure 1.3: HH activity in the adult mouse epidermis.  In telogen skin there are three areas of 
HH activity (blue).  The SHG displays active HH signaling, presumably due to signaling from 
the DP (green).  The UB and TD receive HH signal from sensory nerves (pink) which secrete 













       
Figure 1.4: Sensory innervation during hair follicle morphogenesis.  As the hair follicle 
initiates and grows downwards into the dermis, sensory nerves branch towards the growing 
follicles.  As follicles mature, nerves are restricted to two zones: follicular neural network A 
(FNA) at the follicle opening, and follicular neural network B (FNB) in the sub-glandular region.  













       
Figure 1.5: Neurotrophic factors promote nerve survival. The members of the Neurotrophin 
family (NGF, BDNF, NT-3, NT-4/5) are secreted by target cells and bind to specific Trk 
receptors (TrkA/B/C) and p75 present on nerve terminals.  Once bound, the complex is 

























         
Figure 1.6: Touch dome (TD) morphology and marker expression.  (Top) TDs are present in 
a crescent shape caudally to the opening of guard hair follicles.  (Bottom) Marker expression of 



























         
Figure 1.7: HH signaling and BCC.  Up to 90% of human BCC tumors are caused by loss of 
function mutations in PTCH1, while the remaining 10% are caused by activating mutations in 
SMO.  Vismodegib and itraconazol inhibit SMO by binding at distinct locations.  PSI and 
arsenic trioxide block HH through inhibiting GLI activation and promoting degradation 
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Chapter II – Cutaneous surgical denervation: a method for testing the requirement for 
nerves in mouse models of skin disease 
 
2.1 Abstract 
Cutaneous somatosensory nerves function to detect diverse stimuli that act upon the skin. 
In addition to their established sensory roles, recent studies have suggested that nerves may also 
modulate skin disorders including atopic dermatitis, psoriasis and cancer.  Here, we describe 
protocols for testing the requirement for nerves in maintaining a cutaneous mechanosensory 
organ, the touch dome (TD).  Specifically, we discuss methods for genetically labeling, 
harvesting and visualizing TDs by whole-mount staining, and for performing unilateral surgical 
denervation on mouse dorsal back skin.  Together, these approaches can be used to directly 
compare TD morphology and gene expression in denervated as well as sham-operated skin from 
the same animal.  These methods can also be readily adapted to examine the requirement for 
nerves in mouse models of skin pathology.  Finally, the ability to repeatedly sample the skin 




Over the past few years, there has been a widening appreciation for the influence of 
nerves on diseases not typically regarded as classical neuropathies [1-4].  In the skin, recent 
experimental evidence has suggested that sensory nerves can modulate diverse pathologies 
ranging from psoriasis to cancer [5-9].  This has been demonstrated using techniques such as 
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surgical denervation and pharmacological inhibition of neural function in rodents.  In the case of 
psoriasis, these studies have provided a mechanistic framework for understanding why human 
psoriatic plaques regress following loss of neural function [7, 10-12].  Cutaneous nerves can also 
affect gene expression [13, 14] and are critical for mechanosensing in normal skin [15].  In 
particular, touch dome (TD) epithelia are comprised of a patch of columnar epidermal cells in 
juxtaposition with neuroendocrine Merkel cells innervated by slowly adapting type 1 (SA1) 
nerve fibers [16-18].  TDs mediate light touch sensation and have been shown to display 
Hedgehog pathway activity [5, 19].  TD maintenance depends on innervation [20, 21], as nerves 
secrete Hedgehog ligands to sustain normal TDs and their associated Merkel cells [19].  In 
addition, innervation promotes Hedgehog-dependent tumor formation from TD epithelia [5]. 
Together, these studies reinforce the notion that intricate molecular interactions occurring 
between nerves and the surrounding cells in their niche are crucial for normal TD physiology as 
well as disease. 
To interrogate the nature of these interactions, we describe here a series of in 
vivo techniques for manipulating gene expression in the TD, as well as for harvesting skin 
biopsies for TD visualization after lineage tracing.  Finally, we describe procedures for 
performing unilateral surgical denervation, wherein nerves are removed from one side of the 
mouse dorsal skin, while leaving the contralateral side intact as a sham internal control.  Several 
weeks after surgery, denervated and sham control skin are compared to assess changes that occur 
when nerves are ablated.  Although these techniques are described in the context of normal TDs, 
the denervation procedure has been used to examine the requirement for nerves in mouse models 
of psoriasis [6], wound healing [13] and tumorigenesis [5].  Finally, since the skin is amenable to 
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repeated biopsies, this provides an opportunity to monitor the long-term fates of labeled cells or 
to assess disease progression over multiple time points. 
 
2.3 Protocol  
All procedures described in this protocol were performed in accordance with regulations 
established by the University of Michigan Unit for Laboratory Animal Medicine. 
 
2.3.1 Induce Genetic Recombination in Mice 
 
Note: The Gli1tm3(cre/ERT2)Alj/J mouse strain (Gli1-CreERT2)[22] enables targeting of tamoxifen-
induced genetic recombination to TD epithelia.  Cross this strain with B6.129S4-
Gt(ROSA)26Sortm1Sor/J reporter mice (LacZ)[23] to generate Gli1;LacZ animals to visualize TD 
cells by whole-mount staining below. 
 
1. Prepare tamoxifen solution to a concentration of 12.5 mg/ml in corn oil. 
2. In a 1.5 ml tube, add up to 20 mg of crystalline tamoxifen, and then 1 ml of corn 
oil. Firmly tape the tube to a vortex mixer, and vortex continuously at the highest 
setting at RT until the tamoxifen has fully dissolved (2-4 hr), as confirmed by 
examining the tube under a dissecting microscope for the absence of tamoxifen 
particulates. 
3. Transfer the solution to a 15 ml tube and dilute the tamoxifen to a final 
concentration of 12.5 mg/ml with additional corn oil.  Mix by vortexing the 
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viscous solution for an additional 30 sec.  Store this solution for up to 1 week at 4 
°C in the dark. 
4. Inject the tamoxifen solution intraperitoneally into Gli1;LacZ mice, at a volume of 
200 µl per 20 g of mouse body weight, for an effective tamoxifen dose of 2.5 mg per 
20 g mouse weight. 
 
2.3.2 Harvest Skin Biopsies 
Note: Depending on the experiment, harvest skin biopsies several days to weeks after tamoxifen 
induction.  For all surgeries, follow standard protocols for rodent surgery, including using sterile 
gloves, wearing a surgical mask or hair net, and covering the animal with a sterile surgical drape 
during the procedure. 
1. Prepare 10x stock anesthetic solution by mixing 90 mg/ml ketamine and 6.5 mg/ml 
xylazine in water.  Dilute this stock solution 1:10 into sterile PBS just prior to use, 
and store at RT in the dark for up to 8 months. 
2. Alternatively, anesthetize mice by isoflurane inhalation, beginning with a gas 
concentration of 4% with oxygen to fully anesthetize the animal, and then 
subsequently lowering this to 1-2% for the duration of the procedure. 
3. Inject the anesthetic solution intraperitoneally at a dose of 200 µl per 20 g mouse 
body weight.  Check that the animal has reached the proper plane of sedation by toe 
pinch assay, and confirm that heart and respiratory rates are normal (approximately 
600 beats and 160 breaths per min, respectively). 
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4. Use an electric clipper to remove the hair from the site of biopsy on the dorsal back 
skin, being careful not to nick or damage the underlying skin. 
5. Prepare the surgical site by wiping the shaved area in an anterior-to-posterior 
direction using Betadine and alcohol wipes.  Ensure all hair clippings are removed 
from the site. 
6. Outline the biopsy site using a black marker, place the animal on a warming pad in an 
aseptic surgical area, and cover with a sterile surgical drape (for demonstration 
purposes, sterile drape was omitted to increase visibility).    
Note: To obtain longitudinal sections of hair follicles, the longer edge of the biopsy 
(the edge to be sectioned for histology, ~1 cm) should run in an anterior-posterior 
direction (parallel to the direction of the hair follicles), parasagittal to the dorsal 
midline (FIG 2.1A). 
7. Use a sterile #11 scalpel to make a full thickness excision along the marked area 
without damaging the underlying muscular fascia. 
Note: The excised skin tissue includes the epidermis, dermis, subcutaneous fat and 
panniculus carnosus.  Bleeding is typically minimal. 
8. Flatten the excised skin sample on a dry paper towel, dermis side down, trim away 
the excess paper towel, and store the sample in cold PBS for up to 1 hr if other 
samples need to be collected.  When ready, proceed to Steps 3.1 or 3.2 to process 
samples for histology, or Step 4 for whole-mount β-galactosidase (LacZ) staining. 
9. Suture close the biopsy site using 6-0 nylon sutures, in a simple interrupted pattern 
spaced roughly 3 mm apart. 
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10. Do not return mice that have undergone surgery into the same cage as other animals 
until after full recovery. 
11. Monitor animals immediately after surgery until they regain consciousness, and also 
daily until the surgical area has healed, typically within 1 week.  Use analgesics in 
accordance with designated institutional animal care and use guidelines if mice 
exhibit signs of pain or distress.  Remove sutures within 7-10 days after surgery. 
Note: If needed, prepare analgesic solution by diluting carprofen (50 mg/ml stock 
solution) 1:100 in sterile water.  Inject the solution subcutaneously between the 
shoulder blades near the scruff of the neck, at a dose of 200 µl per 20 g body weight 
(5 mg/kg mouse body weight). 
 
2.3.3 Process Samples for Histology 
Note: To fix and process the excised tissue, use either method below depending on application. 
1. To generate paraffin-embedded histological samples, fix the skin in 3.7% formalin in 
PBS O/N at RT and store in 70% ethanol for up to 2 weeks.  Remove the paper towel 
before embedding into paraffin. 
2. For generating frozen histological samples, submerge the tissue in cold 4% 
paraformaldehyde in PBS and gently shake for 1 hr.  Remove the solution and wash 
the sample with 3 changes of PBS, roughly 5 min each.  Next, submerge the sample in 
30% sucrose in PBS to cryoprotect the tissue ("sucrose sinking"). 
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3. Incubate with gentle shaking O/N at 4 °C.  The next day, remove the paper towel and 
trim away excess adipose tissue from the dermal side of the skin.  Embed the tissue 
directly into OCT and store the frozen block at -80 °C. 
Note: After sectioning, either paraffin or frozen samples can be stained 
by immunohistochemistry to identify TDs, Merkel cells and nerves using antibodies 
against Keratin 17, Keratin 8 and Neurofilament, respectively, as previously described 
[5, 19]. 
 
2.3.4. Visualize Samples by Whole-mount X-Gal Staining 
1. Prepare X-gal staining solution. 
2. Combine 0.94 g sodium phosphate monobasic, and 2.6 g sodium phosphate dibasic 
in 250 ml of sterile water.  Adjust pH to 7.3. To this, add 0.5 ml of 1 M magnesium 
chloride, 0.528 g of potassium ferrocyanide, and 0.412 g of potassium ferricyanide. 
Add 250 µl of octylphenyl-polyethylene glycol and 125 mg of deoxycholate.  The 
base solution can be stored at 4 °C for up to 6 months in the dark. 
3. Prepare 50x stock X-gal solution by adding dimethylformamide to the X-gal stock 
bottle to generate a 50 mg/ml solution.  Store this solution at -20 °C in the dark. 
4. Just prior to use, dilute stock X-gal solution 1:50 into X-gal base solution to 
generate staining solution.  For smaller biopsies (<1 cm2), aliquot 1-2 ml of staining 
solution per sample. 
5. Fix the skin sample collected in Step 2.7 in a solution containing 2% 
paraformaldehyde/0.2% glutaraldehyde in cold PBS for 30 min, gently shaking on ice. 
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For smaller biopsies (<1 cm2), use 1-2 ml of fixative solution per sample. 
Note: Alternatively, fix samples in 2-4% paraformaldehyde only, or in 0.5% 
glutaraldehyde only.  Optimal fixation conditions depend on the tissue, degree of LacZ 
expression and application. 
6. Remove the fixative solution, and rinse samples with 3 changes of PBS, 5 min each, 
on a shaker at RT. 
7. Remove the paper towel underneath the sample and cut away excess adipose tissue 
from the dermal side of the skin by gripping the fat with blunt forceps and trimming 
with dissecting scissors. 
8. Submerge the sample in X-gal staining solution, and incubate at 37 °C O/N. LacZ 
expression will be visible as a blue stain under a dissecting microscope (FIG 2.1B). 
Note: If the signal intensity is weak, replace the staining solution the next day and 
repeat the O/N incubation.  If the background staining is too intense, reduce the time 
of staining, or incubate the sample at RT instead of 37 °C. 
9. Remove the staining solution and wash the samples in 3 changes of PBS containing 
3% DMSO for approximately 5 min, gently shaking at RT. 
10. Wash samples in 2-3 changes of 70% ethanol for 5 min each. Store samples in 70% 
ethanol. 
 
2.3.5. Surgical Denervation 
1. Anesthetize the animal as in Step 2.2 and shave the entire dorsal skin. 
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2. Prepare the surgical area of the back skin using Betadine and alcohol wipes, and cover 
the animal with a sterile surgical drape (for demonstration purposes, sterile drape was 
omitted to increase visibility).  Keep the animal warm using a heating pad while 
operating in an aseptic surgical area. 
3. Make an incision using a sterile #11 scalpel along the dorsal midline from the base of 
the neck to roughly 0.5 cm above the tail. 
4. Using blunt forceps, gently reflect the skin on the left side away from the flank to 
visualize the underlying tissue from the scapular fat pads near the neck to just above 
the hind limb. 
Note: Dorsal cutaneous nerves appear as white strands that travel caudally through the 
translucent fascia of the trunk wall before making sharp bends and entering the loose 
connective tissue underneath the skin (FIG 2.2). 
5. Using ultra-fine forceps under a dissecting light microscope, remove the nerves 
exclusively from the left side of the animal located at anatomical sites T3-12 by 
plucking from where the segments bend at the trunk wall to their entry sites into the 
skin (FIG 2.2). 
6. Orient forceps vertically and remove the nerves by grasping approximately 0.5 cm 
below their bend sites and pulling upwards, causing the nerve to stretch and 
separate from the surrounding tissue (FIG 2.22C-E).  Be careful to avoid rupturing 
adjacent blood vessels. 
7. Continue until all nerves extending from the trunk wall to the skin are removed. Do 
not disrupt the nerves within the dense fascia of the trunk wall.  Keep the tissue 
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moist throughout the procedure by periodically applying drops of sterile 0.9% 
saline solution. 
8. Alternatively, remove nerves by grasping their proximal ends near the trunk wall 
with forceps and snipping with fine scissors.  Afterwards, sever the distal ends near 
the skin (FIG 2.2F-H).  Finally, remove the intervening nerve segments (FIG 2.2I). 
9. Remove any nerves from the skin flap exposed in Step 5.4.  These fibers comprise the 
distal branches of the dorsal cutaneous nerves and appear as white branching strands 
located sporadically within the connective tissue on the dermal side of the skin flap 
(FIG 2.2J-K). 
10. To remove these fine branches, position the fine forceps roughly parallel to the 
dermal surface, grasp the nerves and pluck upwards to avoid disrupting blood 
vessels and puncturing the skin.  Continue until all visible nerves have been 
removed. 
11. Using blunt dissection, reflect the skin on the right side of the dorsal midline incision, 
but do not remove the nerves.  This will serve as the contralateral sham-operated 
control. 
12. Suture along the dorsal midline in a simple interrupted pattern to close the incision. 
Monitor the animal during recovery and post-operatively as previously demonstrated 
(Steps 2.8-10). Remove sutures within 7-10 days after surgery. 
13. To functionally assess stable denervation up to several weeks after surgery, remove the 
hair from the dorsal skin using an electric clipper. 
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14. Gently prick the denervated skin area using a hypodermic needle, and note whether the 
animal responds, typically by shuddering or turning its head.  If the skin area has been 
stably denervated, the animal will exhibit little or no response. 
15. Using a black marker, outline the area of no response, as well as an area of similar size 
and location on the contralateral sham side. 
16. Collect biopsies from these sites as in Steps 2.1-2.9 for analysis. 
Note: Alternatively, the entire dorsal back skin, including denervated and sham-
operated regions, can be removed as a single sheet for whole-mount staining, similar 
to as described in Step 4. 
 
2.4 Representative Results 
By generating mice expressing tamoxifen-inducible Gli1-CreERT2 and a LacZ reporter 
allele, it is possible to visualize TD epithelia and track the fates of these cells over time.  The 
entire denervation procedure typically can be completed within 1 hr per mouse and should cause 
minimal distress to the animal. 
Our previous studies have indicated that nerves are crucial for maintaining both normal 
TDs as well as their associated Keratin 8+ Merkel cells (FIG 2.3A-C) [5, 19].  Nerves are also 
critical for promoting Gli1 expression in the TD (FIG 2.3D).  Given the relatively infrequent 
appearance of TD clusters throughout the skin (FIG 2.1B), it is imperative to sample multiple 
frozen sections to accurately quantitate TD frequency.  Typically, we assess 15 non-consecutive 
sections (each 10 µm thick and ~1 cm long) from both sham and denervated skin from each 
animal.  Following denervation, stable loss of nerves, both at the TD and throughout the skin, 
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can be confirmed by the absence of immunohistochemical staining for standard pan-neural 
markers such as Neurofilament in either frozen or paraffin sections (FIG 2.3A and 2.3C), and as 
previously reported [5]).  Alternatively, nerves can also be identified by expression of β3-tubulin 
or PGP9.5 [6, 9].            
By using Gli1;LacZ mice, it is also possible to confirm both the requirement for nerves in 
activating Hedgehog signaling in the TD and in maintaining TD cell fate by varying the 
sequence of tamoxifen-induced recombination and denervation.  If denervation is performed 
prior to recombination, for instance, this would test the requirement for nerves in activating the 
Hedgehog pathway, as monitored by Cre recombinase activity and levels, which are correlated 
with Gli1 expression in these animals.  On the other hand, if denervation is performed after 
recombination, this would assess the requirement for nerves in maintaining already-labeled cells 
in the TD. 
 
2.5 Discussion 
 Nerves serve crucial functions not only in sensation, but also in mammalian organ 
development, maintenance and regeneration [13, 24-27].  As nerves have recently been 
implicated in diverse skin disorders, the techniques described here can be used to study the 
requirement for innervation in a variety of animal disease models.  Indeed, the unilateral 
denervation technique allows for the direct comparison of skin with either intact or disrupted 
nerves from the same mouse.  This provides an ideal internal control to compensate for animal-
to-animal differences, with subsequent data analyses making use of a paired t-test.  While the 
procedures described here largely utilize the LacZ reporter gene, these experiments can be 
adapted such that the Gli1-CreERT2 allele is combined with other fluorescent reporter or 
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conditional alleles to modify gene expression in the TD.  For instance, Gli1-CreERT2 mice can 
be crossed with animals harboring conditional alleles of Patched1 (B6N.129-
Ptch1tm1Hahn/J)[28] to generate mice that form TD-derived tumors after tamoxifen induction [5]. 
It is important to note that the Gli1-CreERT2 strain also induces recombination in a subset 
of Gli1+hair follicle stem cells that are physically separated from those in the TD [13]. 
 Following denervation, nerves in the skin remain stably ablated for several months (FIG 
2.3C) [5, 19].  In other studies, however, some re-innervation has been reported to occur over 
time [6].  The perdurance of the denervated phenotype may depend on the thoroughness of nerve 
removal, as it is absolutely critical to excise nerve segments between their exit from the chest 
wall to a point close to the sites of insertion into the dermis of the skin. 
 Completely removing the hair from the skin prior to biopsy can enhance the ability to 
subsequently visualize TDs by whole-mount staining (FIG 2.1B).  This is accomplished by 
applying depilatory cream to clipped skin for 2 min, and then wiping the hair away in an 
anterior-to-posterior direction using cotton balls.  Please note that depilation can affect hair cycle 
kinetics by promoting entry into the anagen growth phase.  Alternatively, hair can be completely 
removed using a razor blade.  In addition, whole mount immunohistochemistry can be performed 
to visualize TDs and Merkel cells on epithelial sheets separated from the dermis, as has been 
previously described [29]. 
 The possibility remains that surgical denervation may cause inflammation at the surgical 
site, potentially confounding any observed phenotypes.  In our experience, we have not observed 
significant inflammation after denervation, likely because the collateral tissue damage incurred 
in the skin is slight if the procedure is done properly.  To minimize the possibility that 
inflammation may affect results, additional controls can be incorporated into the experiment.  
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For instance, we observed that denervation specifically inhibited TD-derived tumors, but not 
adjacent hair follicle-associated lesions in the same skin samples, arguing that denervation–and 
not a general wound-induced inflammatory response–likely inhibited tumorigenesis at the TD 
[5]. 
 It is important to note that surgical denervation ablates all cutaneous nerves, including 
sensory and sympathetic fibers [5], and thus provides a general overall assessment of the 
influence of these nerves on either normal or diseased skin.  Other experimental approaches, for 
instance using pharmacologics such as Botulinum neurotoxin to block neurotransmission, may 
yield more detailed mechanistic insights [7], although it is unclear whether these agents inhibit 
retrograde secretion of cytokines such as Hedgehog ligands.  Alternatively, compounds such as 
6-hydroxydopamine have been used to ablate sympathetic nerves in the skin [9].  In addition, 
targeting the receptors for nerve-derived factors such as Calcitonin gene-related peptide and 
Substance P may be useful for interrogating specific interactions between nerves and the 
surrounding cells within their niche [6].  Ultimately, multiple strategies may be utilized in 
combination to identify, or at least rule out, potential signaling mechanisms. 
 Finally, targeted genetic deletion of nerve-derived factors in the neural lineage using 
either Wnt1-Cre or Advillin-Cre may represent the gold standard for elucidating the signals that 
are exchanged between nerves and their niche [19].  As neither of these strains are tamoxifen-
inducible, however, some caution needs to be taken to ensure that disruption of these signals 
does not impair nerve development or proper targeting of neural afferents.  Use of a tamoxifen-
inducible Cre such as Advillin-CreERT2 may help circumvent these issues [30]. 
 Overall, the techniques described here–a combination of lineage tracing, cell 
visualization and surgical denervation–offer powerful approaches for studying the influence of 
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nerves on normal and diseased skin.  With experience, these procedures can be performed 
routinely and reliably, while causing minimal distress to the animal–or the investigator. 
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Figure 2.1 Skin biopsy and whole-mount LacZ staining of TD epithelia.  
A. (Top) Photograph of mouse after biopsy and prior to suturing. (Lower left) Enlarged image of 
biopsy site. (Lower right) Skin sample obtained from biopsy with its dermis side spread flat on a 
dry paper towel. B. Whole-mount LacZ staining of skin from a Gli1;LacZ mouse, 7 days after 
tamoxifen induction, depilated just prior to biopsy to improve skin visualization. 




















Figure 2.2 Two approaches for denervating dorsal skin.  
A. Cartoon diagram of innervated mouse skin. Red dotted lines indicate a single excision made 
along the dorsal midline to expose the underlying musculature on the trunk wall (purple) as well 
as the dermis (grey, asterisk) beneath the reflected skin. Dorsal cutaneous nerves traveling 
caudally appear to "bend" as they leave the trunk wall (the black arrow indicates one such bend). 
Nerve segments to be excised are demarcated by black dotted lines.  
B. Photograph of intact nerves with sites of bending indicated (arrows). Blue arrows point to 2 
nerve segments that will be removed.  
C-D. Photographs showing denervation technique. Using ultra-fine forceps, grip the nerves 0.5 
cm below their sites of bending and pull outwards.  
E. Photograph showing the body cavity after removal of 2 nerve segments (blue arrows). The 
remaining nerves also need to be removed.  
F-G. An alternative approach for nerve removal is depicted, where nerves are snipped at their 
proximal ends just below where they bend (arrowheads) and also distally, close to their site of 
entry into the skin (arrowheads)  
H. Note that the midline incision in these images is longer than typical for the purpose of better 
visualization.  
J. Photograph of dermal side of the reflected skin flap to one side of the midline.  
K. Nerves are outlined (black lines), with larger blood vessels indicated in red. The nerves 
located on the dermis side of the skin flap also need to be excised. Asterisk, underlying dermis 




Figure 2.3 Stable loss of nerves and deterioration of TDs after denervation.  
A. Immunohistochemistry showing TD epithelia with Keratin 8+ Merkel cells (K8, green) and 
Neurofilament+ nerves (NF, red) in sham-operated skin.  
B. Cartoon depiction, with TD epithelia highlighted in purple, Merkel cells in green, and sensory 
nerves in blue.  
C. Immunohistochemistry showing denervated skin (den) lacking Merkel cell-neurite complexes 
within the TD area. Dashed yellow lines, hair follicle epithelium. Asterisk, background staining.  
D. Whole-mount LacZ staining of dorsal back skin from Gli1LacZ/+ mouse 2 weeks after 
unilateral skin denervation. In the box to the left of the healed midline incision (arrow), abundant 
labeled TD epithelia are observed in sham-operated skin. To the right of the midline, TDs are not 






Table 2.1 List of Materials  
Name Company Catalog 
Number 
Comments 
Alcohol prep pads PDI B339  













Cell Signaling C28E10 rabbit antibody, use at 1:500 
concentration 
Betadine prep pads Medline MDS093917  
Carprofen (Rimadyl) Zoetis   
Cordless rechargable 
clipper 
Wahl trimmer model 
8900 
 
Corn Oil Sigma-Aldrich C8267  
Cryostat Leica CM1860  
DAPI ThermoFisher 
Scientific 
D1306 use at 1:1,000 concentration 
Deoxycholate Sigma-Aldrich D6750  
Depilatory Cream Nair N/A  
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Dimethylforamide Sigma-Aldrich 319937  
Dimethyl Sulfoxide 
(DMSO) 
Sigma-Aldrich D8418  
Glutaraldehyde Sigma-Aldrich G5882  
ImmEdge Pen Vector Laboratories H-4000  
Ketamine HCl Hospira NDC 0409-
2051-05 
 
Magnesium chloride Sigma M8266  
Micro cover glass VWR 48404-454  
Micro Slides VWR 48311-703  
10% Neutral Buffered 
Formalin 
VWR BDH0502-4LP  
6-0 nylon sutures DemeTECH NL166012F4P  
Octylphenyl-
polyethylene glycol 
Sigma-Aldrich I8896  
O.C.T. Compound Sakura Tissue-Tek 4583  
Paraformaldehyde Sigma-Aldrich 158127  
Potassium 
ferrocyanide 
Sigma-Aldrich P9387  




Sigma-Aldrich P9791  
Sodium phosphate 
dibasic 
Sigma-Aldrich S5136  
Sucrose Sigma-Aldrich 84097  
Tamoxifen Sigma-Aldrich T5648-1G  
Ultra-fine forceps Dumont 0103-5-PO  
Vectashield Vector Laboratories H1000  
X-gal Roche 10 651 745 001 Dissolve in dimethylforamide 
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Chapter III – Basal cell carcinoma preferentially arises from stem cells within hair follicle 
and mechanosensory niches 
 
3.1 Abstract  
Basal cell carcinoma (BCC) is characterized by frequent loss of PTCH1, leading to constitutive 
activation of the Hedgehog (HH) pathway.  Although the requirement for HH in BCC is well-
established, the identity of disease-initiating cells and the compartments in which they reside remain 
controversial.  By using several inducible Cre drivers to delete Ptch1 in different cell compartments in 
mice, we show here that multiple hair follicle stem cell populations readily form BCC-like tumors.  In 
contrast, stem cells within the interfollicular epidermis do not efficiently form tumors.  Notably, we 
observed that innervated GLI1-expressing progenitors within mechanosensory touch dome epithelia are 
highly tumorigenic.  Sensory nerves activate HH signaling in normal touch domes, while denervation 
attenuates touch dome-derived tumors.  Together, our studies identify varying tumor susceptibilities 
among different stem cell populations in the skin, highlight touch dome epithelia as “hot spots” for 
tumor formation, and implicate cutaneous nerves as mediators of tumorigenesis. 
 
3.2 Introduction 
  Dysregulated Hedgehog (HH) signaling is a hallmark of basal cell carcinoma (BCC), the 
most common cancer in North America [1, 2].  During development and homeostasis, HH is carefully 
regulated by a balance of upstream factors that can either promote signaling, such as Smoothened 
(SMO), or suppress signaling, such as Patched1 (PTCH1).  In BCC, this balance is tilted decisively in 
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favor of pathway activation through mutations that cause either loss of PTCH1 function or constitutive 
activation of SMO [3, 4]. 
Early evidence implicating perturbed HH in BCC came from studies demonstrating that patients 
harboring defective PTCH1 alleles are predisposed to developing numerous BCCs (Gorlin syndrome) 
[3, 5, 6].  Similarly, loss of PTCH1 promotes BCC-like lesions in irradiated mice [7], as does 
overexpression of mutated forms of SMO, Sonic hedgehog (SHH) or downstream GLI transcription 
factors [4, 8-12].  Findings from these and other studies have recently culminated in the USA Food and 
Drug Administration’s approval of GDC-0449 (vismodegib), an oral inhibitor of SMO, as a therapeutic 
for treating advanced BCC [13]. 
  In the skin, multiple stem cell populations maintain tissue homeostasis and contribute to 
organ regeneration during hair cycling [14].  In trying to identify the stem cells which give rise to BCC, 
however, recent studies have yielded conflicting results [15].  For instance, work by Youssef et al., has 
suggested that hair follicle bulge stem cells expressing a constitutively active form of SMO (SmoM2) 
resist BCC formation [16].  Rather, these tumors arise primarily from the interfollicular epidermis (IFE), 
which we have also previously observed in intact and wounded skin [17].  In direct contrast, lineage 
tracing experiments by Wang et al., using irradiated Ptch1 heterozygous animals have suggested that 
Keratin 15+ bulge stem cells are the primary progenitors for BCC [18].  A third possibility—that stem 
cells in the epidermis and bulge are both competent for developing BCC—has also been proposed for 
tumors induced by an activated form of GLI2 [19].   
  These discrepant results are likely due to the use of different animal models 
whereby, in some cases, oncogenic transgenes such as SmoM2 are often driven by heterologous 
promoters.  Because up to 90% of human BCCs are thought to be caused by loss of PTCH1, 
mouse models that target deletion of Ptch1 to specific skin compartments may serve as more 
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accurate models of human disease.  Indeed, deletion of Ptch1 in Lgr5+ stem cells in the lower 
bulge and secondary hair germ has been reported to yield BCC-like tumors [20].  Whether other 
stem cell populations residing in the hair follicle and IFE possess tumor-forming capacity 
currently remains unclear. 
Here we demonstrate that multiple hair follicle stem cell populations are highly tumorigenic 
upon deletion of Ptch1, whereas most stem cells within the IFE do not efficiently form tumors.  
However, an innervated subset of IFE cells known as touch dome (TD) epithelia display activated HH 
signaling during homeostasis and are highly susceptible to tumorigenesis.  Surgical nerve ablation 
blunted the formation of touch dome-derived lesions, suggesting that cutaneous sensory nerves may play 
a previously unrecognized role in skin cancer. 
 
3.3 Materials and Methods 
3.3.1 Animals 
The following mice were used: Gli1tm3(cre/ERT2)Alj (Gli1-Cre ERT2)[21]; Tg(KRT14-cre/ERT)20Efu	
(K14-CreERT)[22];	Hes1tm1(cre/ERT2)Lcm (Hes1-CreERT2)[23]; Lrig1tm1.1(cre/ERT2)Rjc (Lrig1-CreERT2)[24]; 
Gt(ROSA)26Sortm1Sor (ROSA26A-lacZ)[25]; Gt(ROSA)26Sortm1(EYFP)Cos (ROSA26A-YFP)[26]; 
Ptch1tm1Hahn [27]; and Trp53tm1Brn [28]. 
 
3.3.2 Mouse manipulations 
For tumor cell-of-origin experiments, animals were induced with tamoxifen during telogen, at 
7.5 weeks of age.  For nerve studies, mice were induced with tamoxifen and/or denervated according to 
the schedules described in the text.  Mice were treated with tamoxifen as follows:  one dose at 5 mg per 
40 grams body weight for Gli1;Ptch1 and Hes1;Ptch1 mice; one dose at 1 mg per 40 grams body weight 
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for Lrig1;Ptch1 mice; and three daily doses, each 1 mg per 40 grams body weight, for K14;Ptch1 mice.  
Skin biopsies were harvested as previously described[17].  Denervation of dorsal back skin was adapted 
from previously described procedures [29].  Briefly, mice were anesthetized, and a 4.5-5 cm incision 
was made along the dorsal midline to expose the dorsal cutaneous nerves on the left side (T3-12).  These 
were blunt dissected close to their anatomical entry into the skin, while nerves on the right side were left 
intact.  Subsequently, the skin was closed with sutures, similar to the skin biopsies.  All studies were 
performed in accordance with regulations established by the University of Michigan Unit for Laboratory 
Animal Medicine.   
 
3.3.3 Tissue staining 
Biopsies were fixed for 1 hour in cold 3.7% paraformaldehyde, washed and incubated overnight 
in 30% sucrose at 4 degrees, before embedding in OCT mounting media.  Frozen sections were stained 
using standard protocols with the following antibodies: rabbit anti-K17 (D73C7, 1:1,500, Cell 
Signaling); rat anti-K8 (TROMA-I, 1:500, Developmental Studies Hybridoma Bank); rabbit anti-K14 
(AF64, 1:1,000,000, Covance); guinea pig anti-K5 (03-GP-CK5, American Research Products); chicken 
anti-GFP/YFP (GFP-1020, 1:2,000, Aves Labs); rabbit anti-NF-L (C28E10, 1:500, Cell Signaling); rat 
anti-β4-integrin (346-11A, 1:500, BD Pharmingen); rabbit anti-Sox9 (H-90, 1:150, Santa Cruz 
Biotechnology); goat anti-Lrig1 (AF3688, 1:25, R&D Systems); rabbit anti-K10 (PRB-159P, 1:500, 
Covance); rabbit anti-Involucrin (PRB-140C, 1:500, Covance); and rat anti-CD200 eFluor660 (OX90, 
1:2,000, eBioscience).  For frozen samples stained for YFP, sections were pre-treated with cold 
methanol for 5 minutes prior to blocking and incubation with primary antibodies.  For whole-mount β-
gal staining, Gli1 in situ staining and qPCR, see Supplemental Information. 
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3.3.4 Quantitation  
For quantitating TDs and TD-derived tumors, 15 non-consecutive frozen skin sections (each 
10um thick, ~1 cm in length) were co-stained with antibodies against K17 and K8 to label TD epithelia 
and Merkel cells, respectively, for each sample.  TDs were identified based on columnar morphology, 
proximity to guard hairs, K17 expression and association with K8-expressing Merkel cells.  TD size was 
assessed by counting the number of K17+ cells within each cluster along ~15 cm of skin.  TD-derived 
tumors were identified based on similar criteria as those used for normal TDs, and the total number of 
K17+ cells within lesions radiating down from the epidermis was scored.  We were careful to exclude 
K17-expressing suprabasal cells normally found in the hair follicle infundibulum[30].  Importantly, K17 
expression is absent in normal non-TD IFE.  To quantitate hair follicle-associated tumors in Gli1;Ptch1 
mice, we measured tumor volumes from 5 non-consecutive frozen skin sections (each 10 um thick, ~1 
cm in length) for each sample.  We performed IHC for K17, outlined tumors in Photoshop from 20x 
images, and recorded tumor area in pixels.  For quantitating ectopic hair buds in K14;Ptch1 mice, we 
counted the number of cell clusters, defined as consisting of at least 3 continuous K17+ cells, along the 
entire IFE.   
 
3.3.5 Statistics 
  A paired Student’s t-Test was used to assess significance in experiments where 
denervated and sham-operated, matched skin samples were harvested from the same animal.  For all 






3.4.1 BCC-like tumors can arise from multiple hair follicle stem cell populations 
A hair follicle origin for BCC has long been suggested on the basis of similarities in marker 
expression [31, 32].  Because the hair follicle is maintained by several independent stem cell 
populations, we directly tested whether these cells are able to form tumors upon loss of Ptch1.  To target 
PTCH1 deletion to specific hair follicle compartments, we generated mice harboring homozygous 
PTCH1 floxed alleles [33] coupled with different tamoxifen-inducible Cre drivers (FIG 3.1A).  We 
treated mice with tamoxifen at 7.5 weeks of age, then harvested skin biopsies several weeks post-
induction to assess tumor formation. 
During telogen, stem cells expressing the HH target gene GLI1 reside within the hair follicle 
upper and lower bulge and secondary hair germ [34].  In mice expressing Gli1 promoter-driven CreERT2 
and PTCH1 floxed alleles (Gli1;Ptch1), we observed robust tumor formation within 5 weeks after 
tamoxifen induction (FIG 2.1B).  These tumors appeared well circumscribed and displayed BCC-like 
features such as peripheral basal palisading (FIG 3.1C).  As expected, these lesions were typically 
connected to the hair follicle bulge, but not the infundibulum, consistent with the lack of contribution of 
normal GLI1+ stem cells to the hair canal [34].  Although GLI1+ cells can contribute to the regenerating 
hair follicle during anagen, we did not observe tumors associated with the lower anagen follicle, 
suggesting that matrix cells cannot give rise to BCCs (FIG 3.2).   
We have recently reported that mice expressing Hes1-CreERT2 display recombinase activity in 
suprabasal cells of the IFE and infundibulum[30].  By coupling this recombinase with an inducible 
ROSA26R promoter-driven YFP reporter allele, we also observed Cre activity in inner bulge and, less 
frequently, in outer bulge stem cells (FIG 3.1D).  We therefore assessed tumor formation in mice 
expressing this Cre along with PTCH1 floxed alleles (Hes1;Ptch1), and observed upper and lower 
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bulge-associated lesions similar to those in Gli1;Ptch1 animals, within 7 weeks after tamoxifen 
induction (FIG 3.1E).  Together, these data confirm that bulge stem cells can indeed serve as tumor 
progenitors. 
To test whether other stem cell populations can form BCCs, we next focused on LRIG1+ cells in 
the isthmus.  Under homeostatic conditions, these cells renew the hair follicle infundibulum 
independently of bulge stem cells, because bulge cells largely do not contribute to the infundibulum, 
while LRIG1+ stem cells do not contribute to the bulge or anagen follicle [30, 35].  In mice expressing 
Lrig1  promoter-driven CreERT2 and Ptch1 floxed alleles (Lrig1;Ptch1), we also observed numerous 
tumors associated with the isthmus and infundibulum 5 weeks after tamoxifen induction (FIG 3.1F).  
These findings therefore reveal that BCC-like tumors can originate from upper bulge, lower bulge and 
isthmus progenitor populations in the hair follicle. 
 
3.4.2 The IFE displays reduced tumor forming capacity 
To determine whether the epidermis is susceptible to tumor formation, we deleted PTCH1 in the 
IFE using mice expressing Keratin 14 promoter-driven CreERT (K14;Ptch1).  We and others have 
previously shown that this recombinase displays robust activity in IFE stem cells but minimal activity in 
the hair follicle [17, 36], as confirmed here using the YFP reporter allele (FIG 3.3A).  Surprisingly, 
K14;Ptch1 mice did not develop tumors in the epidermis, 5 weeks after induction.  Even after extending 
the interval between tamoxifen treatment and biopsy to 12 weeks, we noticed that K14;Ptch1 animals 
typically possessed a hyperplastic epidermis containing small, ectopic hair follicle-like buds resembling 
early benign follicular hamartomas (FIG 3.3B).  Larger lesions adjacent to the IFE radiated laterally 
from the hair follicle infundibulum and did not display a connection to the epidermis, as confirmed by 
examining serial sections (FIG 3.3B and 3.4).   
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Previous studies have found that P53 mutations are common in human BCC and that loss of P53 
can promote BCCs in the IFE of irradiated Ptch1-heterozygous mice [18, 37, 38].  We therefore 
assessed tumor formation in K14;Ptch1 mice that additionally harbored homozygous floxed alleles of 
P53.  In mice biopsied up to 12 weeks after tamoxifen treatment, however, we observed that loss of P53 
did not enhance IFE tumorigenesis (FIG 3.3C).  In stark contrast, Gli1;Ptch1, Hes1;Ptch1 and 
Lrig1;Ptch1 mice with wild-type P53 all developed large hair follicle-associated lesions that filled the 
dermis within 5-7 weeks post-induction (FIG 3.1).  These findings indicate that BCC-like tumors 
preferentially develop from hair follicle stem cells, and that loss of P53 does not promote IFE tumor 
formation. 
 
3.4.3 Hair follicle-derived tumors express similar markers irrespective of stem cell origin 
Given our finding that BCC-like lesions can originate from multiple hair follicle stem cell 
populations, we next determined whether these tumors display differences in marker expression.  
Regardless of cellular origin, all hair follicle-derived tumors consistently expressed K14 as well as K17, 
a HH pathway target gene  [39, 40] (FIG 3.5A-B).  K17 was also upregulated throughout the 
hyperplastic epidermis of induced K14;Ptch1 animals, indicating that IFE stem cells which had deleted 
PTCH1 remained in the epidermis and activated downstream HH signaling in spite of the absence of 
tumors. 
All hair follicle-derived tumors also expressed the stem markers Sox9 and Lrig1 (FIG 3.5C-D).  
At the same time, these tumors frequently exhibited signs of early differentiation, as evidenced by 
expression of K10 (FIG 3.5E).  In contrast, involucrin, a later differentiation marker, was not observed 
(FIG 3.5F).  Because we were ultimately unable to detect differential marker expression, this suggests 
that all hair follicle-derived tumors display a similar phenotype irrespective of cellular origin. 
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3.4.4 BCC-like tumors efficiently arise from stem cells within touch dome epithelia  
Although the IFE was largely devoid of tumors, we noticed that Gli1;Ptch1 mice frequently 
developed highly branched lesions that radiated down from the epidermis specifically at sites adjacent to 
guard hairs (FIG 3.6A).  Because mechanosensory TD epithelia are localized to guard hairs, we re-
evaluated the activity of Gli1-CreERT2 by generating mice expressing the recombinase along with either a 
ROSA26R promoter-driven β-galactosidase (LacZ) or YFP reporter allele (Gli1;LacZ or Gli1;YFP, 
respectively).  After tamoxifen induction, these mice indeed displayed reporter gene expression in TDs, 
as determined both by whole-mount staining for LacZ (FIG 3.6B) and by co-localizing YFP with K17, a 
marker of TDs [41, 42] (FIG 3.7).  TD labeling was stably maintained in the long term (FIG 3.6B), 
suggesting that TDs are renewed by dedicated stem cell pools that display HH pathway activity under 
homeostasis. 
It is interesting to note that normal TDs typically consist of keratinocytes displaying a columnar 
basal morphology resembling the peripheral palisades observed in hair follicle-associated BCC-like 
tumors (FIG 3.6C).  To establish that epidermis-associated Gli1;Ptch1 tumors are derived from TDs, we 
examined tumor formation at earlier time points and observed a gradual lateral as well as downward 
expansion of K17+ TD-derived cell clusters upon deletion of PTCH1  (FIG 3.6D-E).  Just as normal 
TDs are juxtaposed by innervated neuroendocrine Merkel cells [43], epidermis-associated tumors in 
Gli1;Ptch1 mice were also lined by Merkel cells, as assessed by staining for the marker K8 (FIG 3.6D).  
In addition, neurofilament staining confirmed that tumor-associated Merkel cells were innervated by 
sensory afferents (FIG 3.6F).  In contrast, Merkel cells were not detected near any hair follicle-
associated tumors.   
Infrequently, we also observed more extensive epidermis-associated lesions in K14;Ptch1 mice 
(FIG 3.6G).  These tumors resembled those arising from the TD in Gli1;Ptch1 animals, and staining for 
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K8 confirmed the presence of Merkel cells localized to these tumors (FIG 3.6G).  To assess whether 
K14-CreERT can induce recombination in the TD, we analyzed mice expressing the recombinase along 
with the YFP reporter allele (K14;YFP).  Indeed, TD epithelia were occasionally labeled in K14;YFP 
animals, although at a frequency that was significantly reduced compared to either IFE labeling outside 
of TDs, or labeling within TDs in Gli1;YFP mice (FIG 3.6H-I).  Diminished K14-CreERT activity in the 
TD is likely due to reduced expression of K14 in TDs relative to the rest of the IFE, which is apparent 
only upon high dilution (1:1,000,000) of an antibody against this keratin (FIG 3.6J).  Altogether, our 
findings suggest that TD epithelia activate HH signaling during homeostasis and, unlike the rest of the 
IFE, are highly susceptible to forming BCC-like lesions upon loss of Ptch1.   
 
3.4.5 Surgical denervation inhibits tumorigenesis 
Surgical nerve ablation has been reported to cause loss of TDs and Merkel cells in rodent and 
feline skin [44-46].  To confirm these findings, we denervated thoracic-level cutaneous nerves to one 
side of the dorsal midline in 6-week-old wild-type mice, while leaving the contralateral side intact as a 
sham control.  After collecting samples 3 or 5 weeks after surgery, we observed that denervated skin 
displayed a significant reduction in K17+ TD size and abundance (FIG 3.8A-B).  Merkel cells were lost 
from denervated skin (FIG 3.8B), possibly subsequent to K17 downregulation (FIG 3.8A), while 
remaining Merkel cells were frequently not innervated (FIG 3.8C).  To further assess HH activity after 
denervation, we denervated 6 week old Gli1;LacZ mice and treated these animals with tamoxifen 2 
weeks after surgery (FIG 2.8D).  Four days later, we harvested biopsies for LacZ staining and observed 
reduced TD labeling compared with intact contralateral control (FIG 3.8D).  Given that K17 and GLI1 
are both downstream targets of HH signaling, these findings suggest that cutaneous nerves are crucial 
for maintaining HH pathway activity in the TD niche.   
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We next extended these studies to determine whether denervation can inhibit TD-derived tumors 
in Gli1;Ptch1 mice.  To first confirm that denervation performed subsequent to tamoxifen induction 
does not affect Gli1-CreERT2 recombinase activity in the TD, we induced Gli1;LacZ mice with tamoxifen 
at 5.5 weeks of age, then subsequently denervated one side of the dorsal skin 4 days after induction (FIG 
3.8B).  Two weeks after nerve ablation, we harvested skin biopsies and observed similar patterns of 
LacZ staining in denervated and sham-operated skin (FIG 3.10A).  Thus, although TD epithelia rely on 
nerves to activate HH (FIG 3.8B, D), nerve ablation and consequent loss of HH pathway activity do not 
immediately affect the abundance or distribution of already-labeled cells in the TD, which can persist for 
weeks without neural input [44, 46].   
In Gli1;Ptch1 mice, we utilized the same approach, inducing animals with tamoxifen at 5.5 
weeks of age and subsequently denervating one side of the skin (FIG 3.10B).  Two or five weeks after 
tamoxifen induction, we harvested biopsies and confirmed that cutaneous nerves were stably ablated 
(FIG 3.9).  Although denervation did not affect tumor growth 2 weeks post-induction, we observed a 
significant inhibition of TD-derived tumors in denervated skin 5 weeks after tamoxifen treatment (FIG 
3.10B-C).  In nine of ten mice, fewer TD tumor cells were observed within denervated skin, compared 
to the contralateral sham control (mean = 81.3 versus 35.3 TD-derived tumor cells/cm for sham versus 
denervated skin, respectively; p = 0.017 by paired Student’s t test).  In addition, the number of Merkel 
cells associated with these tumors was also reduced (FIG 3.10C).  This effect was specific to TD-derived 
tumors, as nerve ablation did not significantly affect adjacent hair follicle-associated lesions (FIG 
3.10D), arguing that denervation does not induce a systemic anti-tumorigenic response. 
If epidermis-associated tumors which develop infrequently in K14;Ptch1 mice are derived 
exclusively from TDs, denervation should also prevent BCC-like lesions in these animals.  We therefore 
surgically removed the nerves from dorsal back skin in 6 week old K14;Ptch1 mice, exposed these 
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animals to tamoxifen 2 weeks after surgery, and harvested biopsies after an additional 5 weeks.  
Although nerve ablation did not affect K14-CreERT-mediated recombination in the IFE (FIG 3.10E), the 
formation of rare TD-derived lesions was attenuated in denervated skin  (mean = 20.7 versus 3.9 TD-
derived tumor cells/cm for sham versus denervated skin, respectively; p = 0.04 by paired Student’s t 
test) (FIG 3.10F).  In contrast, the formation of small ectopic buds along the IFE was unaffected.  
Together, our findings in K14;Ptch1 and Gli1;Ptch1 mice indicate that epidermis-associated tumors 
preferentially arise from TD epithelia and that sensory nerves promote the progression of TD-derived 
tumors. 
 
3.4.6 The mechanosensory niche promotes tumorigenesis 
How does the perineural microenvironment foster a pro-tumorigenic niche?  Because TDs 
display heightened Gli1 expression, we investigated the possibility that paracrine signals released by 
sensory neurons can promote canonical HH signaling in the TD.  In mammals, three HH ligands—SHH, 
DHH and IHH—activate the pathway.  After dissecting dorsal root ganglia, where the cell bodies of 
cutaneous sensory nerves are located, we determined by qRT-PCR that these nerves express markedly 
higher levels of all three HH ligands compared with skin epithelia (FIG 3.11A).  These findings are 
concordant with recent data showing that neuron-specific loss of Shh causes deterioration of TDs and 
Merkel cells in adult mice [47].  
Although loss of Ptch1 may seemingly bypass the requirement for HH ligands to induce pathway 
activity in TD-derived tumors, recent studies have shown that PTCH1-deficient skin upregulates a 
related protein, PTCH2, which can also bind HH ligands and suppress downstream signaling [48, 49].  
Indeed, we confirmed by qRT-PCR that Ptch2 expression was increased upon deletion of Ptch1 in 
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K14;Ptch1 mice (FIG 3.11B), suggesting that PTCH2 may dampen HH signaling in tumor-resistant IFE 
(FIG 3.11B). 
To further elucidate why different skin compartments vary in tumor predisposition, we searched 
for molecular differences that might distinguish tumor-susceptible hair follicle and TD compartments, 
from tumor-resistant IFE. The cell surface glycoprotein CD200 is a marker of hair follicle stem cells in 
humans and may promote immune privilege in various organs [50].  CD200 has also recently been 
found to be enriched in cells that can initiate BCC [51].  In mice, CD200 is a marker of TD epithelia 
[52].  and we also observed CD200 throughout the hair follicle, but not in the IFE (FIG 3.11C). 
Furthermore, all hair follicle- and TD-derived tumors strongly expressed CD200, whereas strikingly, 
CD200 was completely absent from hyperplastic IFE or weakly expressed in ectopic IFE buds in 
K14;Ptch1 mice (FIG 3.11D). In keratinocytes, either loss of Ptch1 or pharmacological activation of HH 
signaling elevated CD200 (FIG 3.11E and F). Together, these findings suggest that in tumor-resistant 
IFE, loss of Ptch1 only partially activates the HH signaling program, leading to upregulation of some 
target genes (Gli1, Ptch2, K17), but not others (CD200) (FIG 3.11B and 3.12). Within the TD niche, 
nerve-derived factors, possibly involving HH ligands, may potentiate full pathway activation and 
tumorigenesis. Notably, as normal TDs resemble BCCs in terms of basal columnar morphology as well 
as elevated baseline expression of GLI1, K17 and CD200, this once again argues that TDs are ‘‘hot 
spots’’ in the epidermis that are primed for tumor formation.  
 
3.5 Discussion 
The precise cellular origin of BCC has been controversial, as recent studies have seemingly 
reported diametrically opposed results.  Whereas SMO-M2-induced BCC-like tumors appear to arise 
from stem cells in the IFE, but not from the hair follicle bulge [53, 54], tumors driven by loss of Ptch1 
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have been reported to originate from the bulge and secondary hair germ (SHG), but not the IFE [18, 20].   
Our results are concordant with those of Wang et al., and Kasper et al., although we have identified 
additional stem cell populations that are also susceptible to tumorigenesis [18, 20].  Altogether, using a  
mouse model that recapitulates the most common genetic aberration seen in human BCCs, our findings 
indicate that these tumors preferentially arise from stem cells located specifically in the upper bulge, 
lower bulge/SHG, isthmus, and TD, but not from IFE stem cells or transit-amplifying matrix cells (FIG 
3.12G). 
What predisposes certain cutaneous epithelia to forming tumors upon loss of Ptch1?  Previous 
studies have postulated that degradation of GLI proteins may restrict HH signaling and BCC formation 
in the skin [11, 55].  Supportive of this, Grachtchouk et al., showed that upon forced activation of 
downstream HH signaling, BCC-like tumors can arise from both hair follicles and IFE [56]. 
Alternatively, upregulation of PTCH2 in the absence of PTCH1 may also restrain full HH pathway 
activity. Indeed, Adolphe et al., recently demonstrated that mice lacking both PTCH1 and PTCH2 
develop a more severe hyperplastic and BCC-like invaginating epidermal phenotype than do mice 
deficient for PTCH1 alone [48]. Our findings are concordant with these observations and suggest that 
tumor-resistant IFE cells become oncogenic only upon high activation of HH signaling requiring loss of 
multiple redundant inhibitors of the pathway. These data further suggest that sites in the skin which 
normally display high level HH signaling are likely predisposed to BCC formation and that loss 
of Ptch1 alone at these sites is sufficient for tumorigenesis. 
Consistent with this concept, we have found that TD epithelia display activated HH signaling 
during homeostasis and are highly susceptible to forming tumors. Under normal conditions, TDs 
function as mechanosensory organs that detect light touch and transduce signals via underlying Merkel 
cells to slowly adapting type 1 sensory afferents [57, 58]. We have further shown that cutaneous sensory 
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nerves express HH ligands and that denervation impairs HH activity in the TD and inhibits the 
progression of TD-derived tumors. Although these results suggest that nerve endings secrete HH ligands 
to promote TD-derived tumors, it is important to add, however, that TD-derived tumors did not appear 
to respond to a neutralizing antibody generated against Shh (FIG 3.13D).  These results might be 
explained if multiple HH ligands simultaneously promote TD-derived tumors, and tumor inhibition can 
be achieved only by complete and sustained impairment of HH signaling, as might occur following 
long-term denervation. These findings do not rule out the possibility that nerves may also non-
canonically activate downstream HH signaling via pathways such as TGF-β [59]. Alternatively, 
cutaneous nerves are known to secrete cytokines such as calcitonin gene-related peptide as well as 
substance P, which can serve functional roles during epidermal development and pathology [60].  
Indeed, neural changes are often observed in patients with psoriasis and atopic eczema, and nerve 
removal inhibits the epidermal hyperplasia observed in experimental models of these diseases [61, 62]. 
Our findings complement those of previous studies showing that nerves can influence tumors in 
other organs. For instance, chemical denervation can inhibit tumorigenesis in the stomach and colon 
[63].  More recent studies in prostate cancer have found that peritumoral sympathetic nerves promote 
tumor growth, while intratumoral parasympathetic nerves stimulate metastasis [64]. In addition, β-
blockers, which interfere with the sympathetic nervous system, can delay the progression of various 
cancers [65].  A tumor-modulatory role for nerves has not been described for Merkel cell carcinoma, a 
rare cancer thought to originate from Merkel cells, but would not be surprising given the close 
association between nerve endings and mechanosensory cells. 
In humans, BCCs primarily develop in sun-exposed, hair-bearing skin. In addition, the majority 
of tumors (between 57% and 78%) typically display a nodular phenotype, while only a minority (15%–
16%) present as superficial lesions [66, 67].  Interestingly, Grachtchouk et al., previously noted in mice 
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that tumors originating from hair follicles appear nodular, whereas IFE-associated tumors resemble 
superficial human BCCs, suggesting that tumor histologic phenotype can reflect cellular origin [56]. 
From this perspective, the high prevalence of nodular human BCCs is consistent with our finding that 
hair follicle stem cells likely serve as the primary progenitors for these tumors. Although our studies do 
not exclude the possibility that loss of Ptch1 may give rise to tumors from the IFE after an extended 
latency, our findings also suggest that some human BCCs that appear to arise from the IFE might 
actually originate from the TD. 
Because Merkel cells are invariably associated with TD-derived tumors in our studies, we also 
examined the distribution of these cells in a limited number of human BCC samples. In four of ten 
tumors, we observed clusters of Merkel cells located within small tumor foci from both superficial and 
deeper lesions, but not within larger tumor masses (FIG 3.11H and 3.14). These observations are 
consistent with a potential mechanosensory niche for BCC, or possibly even “micro-niches” within the 
immediately vicinity of innervated Merkel cells, which in humans are widely distributed not just in TDs, 
but also throughout the skin and hair follicles [68]. Moreover, these cells are particularly abundant in 
glabrous skin [69], where palmoplantar pits frequently develop in Gorlin patients. Merkel cells have also 
been observed in a minority of human BCCs, including a subtype known as fibroepithelioma of Pinkus 
[70, 71], but are more commonly associated with trichoblastoma [72]. It remains to be seen whether 
Merkel cells play an early supporting role during BCC tumor initiation, but are subsequently lost as the 
tumor expands. Further work will be required to determine whether both Merkel cells and nerves 
preferentially associate with specific BCC subtypes, or possibly early during tumorigenesis, and if so, 
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Figure 3.1 Multiple hair follicle stem cell populations readily form BCC-like tumors.  
A.  Schematic showing areas of activity (blue) for the different inducible Cre recombinases used in this 
study. Asterisk indicates TD epithelia. Yellow indicates sebaceous glands. 
B.  Hematoxylin and eosin (H&E) staining showing that Gli1;Ptch1 mice, but not control animals, 
develop numerous hair follicle-associated tumors 5 weeks after tamoxifen (TAM). 
C.  Higher magnification views of hair follicle-associated tumors with peripheral palisading 
(dotted line). 
D.  Hes1-CreERT2-mediated recombination of a floxed YFP reporter allele (green) in suprabasal 
cells of the epidermis, infundibulum, and, less frequently, in the bulge, 3 days (left) or 50 days 
(right) post-TAM. E. Hes1;Ptch1 mice develop bulge-associated tumors, 7 weeks post-TAM. 
(Right) A higher magnification view of the region indicated by the asterisk.                                                                           
F.  Lrig1;Ptch1 mice develop tumors associated with the isthmus and infundibulum, 5 weeks 
post-TAM. 
The scale bars represent 50 µm. See also FIG 3.2. 
 
 
suggesting that cutaneous sensory nerves may play a previously
unrecognized role in skin cancer.
RESULTS
BCC-like Tumors Can Arise from Multiple Hair Follicle
Stem Cell Popul tions
A hair follicle origin for BCC has long been suggested on the ba-
sis of similarities in marker expression (Jih et al., 1999; Schirren
et al., 1997). Because the hair follicle is maintained by several in-
dependent stem cell populations, we directly tested whether
these cells are able to form tumors upon loss of Ptch1. To target
Ptch1 deletion to specific hair follicle compartments, we gener-
ated mice harboring homozygous Ptch1 floxed alleles (Nitzki
et al., 2012) coupled with different tamoxifen-inducible Cre
drivers (Figure 1A). We treated mice with tamoxifen at 7.5 weeks
of age, then harvested skin biopsies several weeks post-induc-
tion to assess tumor formation.
During telogen, stem cells expressing the Hh target gene Gli1
reside within the hair follicle upper and lower bulge and second-
ary hair germ (Brownell et al., 2011). In mice expressingGli1 pro-



































Figure 1. Multiple Hair Follicle Stem Cells Readily Form BCC-like Tumors
(A) Schematic showing areas of activity (blue) for the different inducible Cre recombinases used in this study. Asterisk indicates TD epithelia. Yellow indicates
sebaceous glands.
(B) Hematoxylin and eosin (H&E) staining showing that Gli1;Ptch1mice, but not control animals, develop numerous hair follicle-associated tumors 5 weeks after
tamoxifen (TAM).
(C) Higher magnification views of hair follicle-associated tumors with peripheral palisading (dotted line).
(D) Hes1-CreERT2-mediated recombination of a floxed YFP reporter allele (green) in suprabasal cells of the epidermis, infundibulum, and, less frequently, in the
bulge, 3 days (left) or 50 days (right) post-TAM.
(E) Hes1;Ptch1 mice develop bulge-associated tumors, 7 weeks post-TAM. (Right) A higher magnification view of the region indicated by the asterisk.
(F) Lrig1;Ptch1 mice develop tumors associated with the isthmus and infundibulum, 5 eeks post-TAM.
The scale bars represent 50 mm. See also Figure S1.




Figure 3.2 Lower anagen follicles do not form tumors in Gli1;Ptch1 mice.  H&E staining showing 




































Figure 3.3 IFE stem cells do not efficiently form tumors   
A.  IHC showing that K14-CreERT induces recombination of a YFP reporter allele (green) primarily in 
basal cells of the epidermis, as marked by integrin β4 (red). 
B.  K14;Ptch1 mice develop small ectopic IFE-associated buds, 5 weeks  after TAM.  By 12 weeks post-
TAM, the IFE is hyperplastic but largely devoid of lesions.  Tumors adjacent to the IFE (arrows) are 
typically connected to hair follicles, as shown in serial sections (see also FIG 3.4).   
C.  Loss of p53 does not promote IFE tumor formation, 12 weeks post-TAM.   
 












by staining for th marker K8 (Figure 4D). In addition, neurofila-
ment staining confirmed that tumor-associated Merkel cells
were innervated by sensory afferents (Figure 4F). In contrast,
Merkel cells were never detected near any hair follicle-associ-
ated tumors (Figure 4F).
Infrequently, we also observed more extensive epidermis-
associated lesions in K14;Ptch1mice (Figure 4G). These tumors
resembled those arising from the TD in Gli1;Ptch1 animals, and
staining for K8 confirmed the presence of Merkel cells localized
to these tumors (Figure 4G). To assess whether K14-CreERT can
induce recombination in the TD, we analyzed mice expressing
the recombinase along with the YFP reporter allele (K14;YFP).
Indeed, TD epithelia were occasionally labeled in K14;YFP ani-
mals, although at a frequency that was significantly reduced
compared with either IFE labeling outside of TDs or labeling
within TDs in Gli1;YFP mice (Figures 4H and 4I). Diminished
K14-CreERT activity in the TD is likely due to r duced expression
of K14 in TDs relative to the rest of the IFE, which is apparent only
upon high dilution (1:1,000,000) of an antibody against this
keratin (Figure 4J). Altogether, our findings suggest that TD
epithelia activate Hh signaling during homeostasis and, unlike
the rest of the IFE, are highly susceptible to forming BCC-like
lesions upon loss of Ptch1.
Surgical Denervation Inhibits Tumorigenesis
Surgical nerve ablation has been reported to cause loss of TDs
and Merkel cells in rodent and feline skin (English et al., 1983;
Nurse et al., 1984). To confirm these findings, we denervated
thoracic-level cutaneous nerves to one side of the dorsal midline
in 6-week-old wild-typemice, while leaving the contralateral side
intact as a sham control. After collecting samples 3 or 5 weeks





































Figure 2. IFE Stem Cells Do Not Efficiently Form Tumors
(A) IHC showing that K14-CreERT induces recombination of a YFP reporter allele (green) primarily in basal IFE cells, as marked by integrin b4 (red).
(B) K14;Ptch1mice develop small ectopic IFE-associated buds, 5 weeks after TAM. By 12 weeks post-TAM, the IFE is hyperplastic but largely devoid of lesions.
Tumors adjacent to the IFE (arrows) are typically connected to hair follicles, as shown in serial sections (Figure S2).
(C) L ss of p53 does not promote IFE tumor formatio , 12 weeks post-TAM.
The scale bars represent 50 mm.




Figure 3.4   IFE lesions do not progress in K14;Ptch1 mice.    
Nine serial sections of skin from a K14;Ptch1 mouse, 12 weeks after tamoxifen induction, 
immunostained for K5 (red).  In the left column of panels, (*) marks a similar region of the skin 
overlying a hair follicle that is magnified in the right column of panels.  Hair follicle-associated tumors 
(white dotted lines) and a smaller IFE-associated ectopic bud (yellow dotted line) are indicated in the top 
right panel.  White arrows indicate areas where tumorigenic lesions are continuous with the hair follicle.  
Yellow arrows indicate areas where a smaller ectopic bud is possibly continuous with the IFE (sections 
























Figure 3.5 Hair follicle-derived tumors express similar markers regardless of cellular origin.  
A-F.  IHC for (A) K14, (B) K17, (C) Sox9, (D) Lrig1, (E) K10, and (F) Involucrin (Inv).   
Wild-type telogen hair follicles were from 7.5-week-old mice.  Gli1;Ptch1 and Lrig1;Ptch1 tumors were 
collected 5 weeks post-TAM, while Hes1;Ptch1 and K14;Ptch1 samples were harvested 7 and 12 weeks 
post-TAM, respectively.  Arrows indicate follicles where the bulge is visible.   
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Figure 3.6 TDs are hot spots for tumor formation.   
A.  H&E staining of a TD-associated lesion (asterisk) in Gli1;Ptch1 mice, 5 weeks post-TAM (left).  
(Right), higher magnification view of TD-associated lesion.   
B.  (Top) Whole mount LacZ staining of skin from Gli1;LacZ mice, 7 days (left) and 50 days (middle) 
post-TAM.  (Right) LacZ staining showing TD labeling.  (Bottom) IHC for YFP (green) and K17 (red) 
in a TD from a Gli1;YFP mouse, 35 days post-TAM. 
C.  Resemblance of TD columnar basal cells with palisading periphery of a Gli1;Ptch1 tumor (dotted 
lines).   
D.  (Top left) IHC of a normal TD, identified by K17 expression (red) and underlying K8+ Merkel cells 
(green).  (Right) tumorigenic TDs from Gli1;Ptch1 mice, 2 and 5 weeks post-TAM.   
E.  Quantitation of K17+ cells in the IFE and TD size in Gli1;Ptch1 mice or controls, 2 and 5 weeks 
post-TAM.   
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Figure 4. TDs Are Hot Spots for Tumor Formation
(A) H&E staining of a TD-associated lesion (asterisk) in Gli1;Ptch1 mice, 5 weeks post-TAM (left). (Right) Higher magnification view of TD-associated lesion.
(B) (Top)Whole-mount LacZ staining of skin fromGli1;LacZmice, 7 days (left) and 50 days (middle) post-TAM. (Right) LacZ staining showing TD labeling. (Bottom)
IHC for YFP (green) and K17 (red) in a TD from a Gli1;YFP mouse, 35 days post-TAM.
(C) Resemblance of TD columnar basal cells with palisading periphery of a Gli1;Ptch1 tumor (dotted lines).
(D) (Top left) IHC of a normal TD, identified by K17 expression (red) and underlying K8+Merkel cells (green). (Right) Tumorigenic TDs fromGli1;Ptch1mice, 2 and
5 w eks post-TAM.
(E) Quantitation of K17+ cells in the IFE and TD size in Gli1;Ptch1 mice or controls, 2 and 5 weeks post-TAM.
(F) (Top) TD-derived K5+ tumor (red) ret ini g u derlying Merkel cells (yellow) associated with nerves, as id ntified by neurofilam nt (NF, green). (Bottom) Hair
follicle-associated tumors (red) with nerves in the dermis (green), but no Merkel cells.
(G) K8+ Merkel cells (arrow) are associated with infrequent IFE-derived tumors, suggesting a TD origin. (Inset) Enlarged view.
(H) K14-CreERT displays infrequent recombination in K17+ TD epithelia (red), and frequent recombination in the rest of the IFE, as assessed by YFP reporter
expression (green).
(I) Quantitation of Gli1-CreERT2 and K14-CreERT recombination rates in TD and non-TD IFE. NR, no recombination detected in non-TD IFE in Gli1;YFP mice.
(J) Reduced expression of K14 (red) in TDs overlying Merkel cells (green). The right panel is identical to the left, but with DAPI omitted.
Data are represented as mean ± SEM. The scale bars represent 50 mm.
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F.  (Top) TD-derived K5+ tumor (red) retaining underlying Merkel cells (yellow) associated with 
nerves, as identified by neurofilament (NF, green).  (Bottom) hair follicle-associated tumors (red) with 
nerves in the dermis (green), but no Merkel cells.   
G.  K8+ Merkel cells (arrow) are associated with infrequent IFE-derived tumors, suggesting a TD 
origin.  (Inset) enlarged.   
H.  K14-CreERT displays infrequent recombination in K17+ TD epithelia (red), and frequent 
recombination in the rest of the IFE, as assessed by YFP expression (green).   
I.  Quantitation of Gli1-CreERT2 and K14-CreERT recombination rates in TD and non-TD IFE.  NR, no 
recombination detected in non-TD IFE in Gli1;YFP mice.   
J.  Reduced expression of K14 (red) in TDs epithelia Merkel cells (green).  Right panel is identical to 


















Figure 3.7 Gli1-CreERT2 labels TD epithelia.    
A. IHC showing stable labeling of TD epithelia (red) by Gli1-CreERT2-induced recombination of a floxed 
YFP reporter allele (green), in Gli1;YFP mice, 3 or 42 days post-TAM. 
B. The ratio of K8+ Merkel cells to K17+ TD epithelia is increased, 3 weeks after denervation, relative 
to sham-operated control (p = 0.048). Five weeks after denervation, this ratio is unchanged between 
denervated and sham-operated control skin. This suggests that while denervation decreases the overall 
number of both K17+ TD cells and K8+ Merkel cells (FIG 3.5B), loss of K17 expression occurs more 
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